BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Megraud F, Coenen S, Versporten A, Kist M, Lopez-Brea M, Hirschl AM, Andersen LP, Goossens H, Glupczynski Y; Study Group participants. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut. 2013;62:34-42. [PMID: 22580412 DOI: 10.1136/gutjnl-2012-302254] [Cited by in Crossref: 527] [Cited by in F6Publishing: 447] [Article Influence: 58.6] [Reference Citation Analysis]
Number Citing Articles
1 Suzuki S, Gotoda T, Kusano C, Ikehara H, Ichijima R, Ohyauchi M, Ito H, Kawamura M, Ogata Y, Ohtaka M, Nakahara M, Kawabe K. Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan. Gut. 2020;69:1019-1026. [PMID: 31915235 DOI: 10.1136/gutjnl-2019-319954] [Cited by in Crossref: 32] [Cited by in F6Publishing: 21] [Article Influence: 32.0] [Reference Citation Analysis]
2 Morgan DR, Torres J, Sexton R, Herrero R, Salazar-Martínez E, Greenberg ER, Bravo LE, Dominguez RL, Ferreccio C, Lazcano-Ponce EC, Meza-Montenegro MM, Peña EM, Peña R, Correa P, Martínez ME, Chey WD, Valdivieso M, Anderson GL, Goodman GE, Crowley JJ, Baker LH. Risk of recurrent Helicobacter pylori infection 1 year after initial eradication therapy in 7 Latin American communities. JAMA 2013;309:578-86. [PMID: 23403682 DOI: 10.1001/jama.2013.311] [Cited by in Crossref: 54] [Cited by in F6Publishing: 44] [Article Influence: 6.8] [Reference Citation Analysis]
3 Meliț LE, Mărginean CO, Mărginean CD, Mărginean MO. The Relationship between Toll-like Receptors and Helicobacter pylori-Related Gastropathies: Still a Controversial Topic. J Immunol Res 2019;2019:8197048. [PMID: 30863783 DOI: 10.1155/2019/8197048] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 9.5] [Reference Citation Analysis]
4 Uotani T, Miftahussurur M, Yamaoka Y. Effect of bacterial and host factors on Helicobacter pylori eradication therapy. Expert Opin Ther Targets. 2015;19:1637-1650. [PMID: 26245678 DOI: 10.1517/14728222.2015.1073261] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
5 Rojas García P, van der Pol S, van Asselt ADI, Postma M, Rodríguez-Ibeas R, Juárez-Castelló CA, González M, Antoñanzas F. Efficiency of Diagnostic Testing for Helicobacter pylori Infections-A Systematic Review. Antibiotics (Basel) 2021;10:55. [PMID: 33430005 DOI: 10.3390/antibiotics10010055] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Saleem N, Howden CW. Update on the Management of Helicobacter pylori Infection. Curr Treat Options Gastroenterol 2020;:1-12. [PMID: 32837180 DOI: 10.1007/s11938-020-00300-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
7 Güven B, Gülerman F, Kaçmaz B. Helicobacter pylori resistance to clarithromycin and fluoroquinolones in a pediatric population in Turkey: A cross-sectional study. Helicobacter 2019;24:e12581. [PMID: 30950125 DOI: 10.1111/hel.12581] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
8 Tavares AF, Parente MR, Justino MC, Oleastro M, Nobre LS, Saraiva LM. The bactericidal activity of carbon monoxide-releasing molecules against Helicobacter pylori. PLoS One 2013;8:e83157. [PMID: 24386154 DOI: 10.1371/journal.pone.0083157] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
9 Biernat MM, Bińkowska A, Łaczmański Ł, Biernat P, Krzyżek P, Gościniak G. Phenotypic and Genotypic Analysis of Resistant Helicobacter pylori Strains Isolated from Children with Gastrointestinal Diseases. Diagnostics (Basel) 2020;10:E759. [PMID: 32992661 DOI: 10.3390/diagnostics10100759] [Reference Citation Analysis]
10 Chen M, Wu M, Chen C, Chen C, Fang Y, Bair M, Chang C, Lee J, Hsu W, Luo J, Lin J, Liou J; Taiwan Gastrointestinal Disease and Helicobacter Consortium. Impact of amoxicillin resistance on the efficacy of amoxicillin-containing regimens for Helicobacter pylori eradication: analysis of five randomized trials. Journal of Antimicrobial Chemotherapy 2017;72:3481-9. [DOI: 10.1093/jac/dkx320] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
11 Liou JM, Chang CY, Chen MJ, Chen CC, Fang YJ, Lee JY, Wu JY, Luo JC, Liou TC, Chang WH, Tseng CH, Wu CY, Yang TH, Chang CC, Wang HP, Sheu BS, Lin JT, Bair MJ, Wu MS; Taiwan Gastrointestinal Disease and Helicobacter Consortium. The Primary Resistance of Helicobacter pylori in Taiwan after the National Policy to Restrict Antibiotic Consumption and Its Relation to Virulence Factors-A Nationwide Study. PLoS One. 2015;10:e0124199. [PMID: 25942450 DOI: 10.1371/journal.pone.0124199] [Cited by in Crossref: 59] [Cited by in F6Publishing: 48] [Article Influence: 9.8] [Reference Citation Analysis]
12 Agudo-fernández S, González Blanco A. Análisis retrospectivo del uso de la cuádruple terapia con bismuto (Pylera®) en la práctica clínica real en España. Gastroenterología y Hepatología 2018;41:483-9. [DOI: 10.1016/j.gastrohep.2018.05.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
13 Macías-garcía F, Llovo-taboada J, Díaz-lópez M, Bastón-rey I, Domínguez-muñoz JE. High primary antibiotic resistance of Helicobacter Pylori strains isolated from dyspeptic patients: A prevalence cross-sectional study in Spain. Helicobacter 2017;22:e12440. [DOI: 10.1111/hel.12440] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 5.5] [Reference Citation Analysis]
14 Lim SG, Park RW, Shin SJ, Yoon D, Kang JK, Hwang JC, Kim SS, Kim JH, Lee KM. The relationship between the failure to eradicate Helicobacter pylori and previous antibiotics use. Dig Liver Dis 2016;48:385-90. [PMID: 26856963 DOI: 10.1016/j.dld.2015.12.001] [Cited by in Crossref: 35] [Cited by in F6Publishing: 19] [Article Influence: 5.8] [Reference Citation Analysis]
15 Ortiz V, Estevez-Ordonez D, Montalvan-Sanchez E, Urrutia-Argueta S, Israel D, Krishna US, Romero-Gallo J, Wilson KT, Peek RM, Dominguez R, Morgan DR. Helicobacter pylori antimicrobial resistance and antibiotic consumption in the low-resource Central America setting. Helicobacter 2019;24:e12595. [PMID: 31111610 DOI: 10.1111/hel.12595] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
16 Almeida N, Romãozinho JM, Donato MM, Luxo C, Cardoso O, Cipriano MA, Marinho C, Fernandes A, Calhau C, Sofia C. Helicobacter pylori antimicrobial resistance rates in the central region of Portugal. Clin Microbiol Infect 2014;20:1127-33. [PMID: 24890952 DOI: 10.1111/1469-0691.12701] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
17 Bilgilier C, Stadlmann A, Makristathis A, Thannesberger J, Kastner MT, Knoflach P, Steiner P, Schöniger-Hekele M, Högenauer C, Blesl A, Datz C, Huber-Schönauer U, Schöfl R, Wewalka F, Püspök A, Mitrovits N, Leiner J, Tilg H, Effenberger M, Moser M, Siebert F, Hinterberger I, Wurzer H, Stupnicki T, Watzinger N, Gombotz G, Hubmann R, Klimpel S, Biowski-Frotz S, Schrutka-Kölbl C, Graziadei I, Ludwiczek O, Kundi M, Hirschl AM, Steininger C; Austrian Helicobacter Study Group of the Austrian Society of Gastroenterology and Hepatology. Prospective multicentre clinical study on inter- and intrapatient genetic variability for antimicrobial resistance of Helicobacter pylori. Clin Microbiol Infect 2018;24:267-72. [PMID: 28669844 DOI: 10.1016/j.cmi.2017.06.025] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
18 Su J, Zhou X, Chen H, Hao B, Zhang W, Zhang G. Efficacy of 1st-line bismuth-containing quadruple therapies with levofloxacin or clarithromycin for the eradication of Helicobacter pylori infection: A 1-week, open-label, randomized trial. Medicine (Baltimore) 2017;96:e5859. [PMID: 28207505 DOI: 10.1097/MD.0000000000005859] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
19 Seddik H, Ahid S, El Adioui T, El Hamdi FZ, Hassar M, Abouqal R, Cherrah Y, Benkirane A. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a prospective randomized study. Eur J Clin Pharmacol. 2013;69:1709-1715. [PMID: 23695545 DOI: 10.1007/s00228] [Reference Citation Analysis]
20 Siddique O, Ovalle A, Siddique AS, Moss SF. Helicobacter pylori Infection: An Update for the Internist in the Age of Increasing Global Antibiotic Resistance. The American Journal of Medicine 2018;131:473-9. [DOI: 10.1016/j.amjmed.2017.12.024] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 7.7] [Reference Citation Analysis]
21 Klesiewicz K, Karczewska E, Budak A, Marona H, Szkaradek N. Anti-Helicobacter pylori activity of some newly synthesized derivatives of xanthone. J Antibiot 2016;69:825-34. [DOI: 10.1038/ja.2016.36] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
22 Okamura T, Suga T, Nagaya T, Arakura N, Matsumoto T, Nakayama Y, Tanaka E. Antimicrobial resistance and characteristics of eradication therapy of Helicobacter pylori in Japan: a multi-generational comparison. Helicobacter. 2014;19:214-220. [PMID: 24758533 DOI: 10.1111/hel.12124] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 4.9] [Reference Citation Analysis]
23 Cellini L, Di Campli E, Di Bartolomeo S, Bessa LJ, Baffoni M, Di Giulio M. New transport medium for cultural recovery of Helicobacter pylori. J Clin Microbiol. 2014;52:4325-4329. [PMID: 25320229 DOI: 10.1128/jcm.02850-14] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
24 Karabiber H, Selimoglu MA, Otlu B, Yildirim O, Ozer A. Virulence factors and antibiotic resistance in children with Helicobacter pylori gastritis. J Pediatr Gastroenterol Nutr. 2014;58:608-612. [PMID: 24792628 DOI: 10.1097/mpg.0000000000000273] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
25 Keogan DM, Griffith DM. Current and potential applications of bismuth-based drugs. Molecules 2014;19:15258-97. [PMID: 25251194 DOI: 10.3390/molecules190915258] [Cited by in Crossref: 81] [Cited by in F6Publishing: 42] [Article Influence: 11.6] [Reference Citation Analysis]
26 Boyanova L, Ilieva J, Gergova G, Mitov I. Levofloxacin susceptibility testing against Helicobacter pylori : evaluation of a modified disk diffusion method compared to E test. Diagnostic Microbiology and Infectious Disease 2016;84:55-6. [DOI: 10.1016/j.diagmicrobio.2015.09.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
27 Dang NQH, Ha TMT, Nguyen ST, Le NDK, Nguyen TMT, Nguyen TH, Pham TTH, Tran VH. High rates of clarithromycin and levofloxacin resistance of Helicobacter pylori in patients with chronic gastritis in the south east area of Vietnam. J Glob Antimicrob Resist 2020;22:620-4. [PMID: 32590188 DOI: 10.1016/j.jgar.2020.06.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
28 Rizvanov AA, Haertlé T, Bogomolnaya L, Talebi Bezmin Abadi A. Helicobacter pylori and Its Antibiotic Heteroresistance: A Neglected Issue in Published Guidelines. Front Microbiol 2019;10:1796. [PMID: 31456763 DOI: 10.3389/fmicb.2019.01796] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
29 Federico A, Gravina AG, Miranda A, Loguercio C, Romano M. Eradication of Helicobacter pylori infection: Which regimen first? World J Gastroenterol. 2014;20:665-672. [PMID: 24574740 DOI: 10.3748/wjg.v20.i3.665] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
30 Cellini L, Di Bartolomeo S, Di Campli E, Genovese S, Locatelli M, Di Giulio M. In vitro activity of Aloe vera inner gel against Helicobacter pylori strains. Lett Appl Microbiol 2014;59:43-8. [PMID: 24597562 DOI: 10.1111/lam.12241] [Cited by in Crossref: 28] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
31 Amar N, Peretz A, Gerchman Y. A cheap, simple high throughput method for screening native Helicobacter pylori urease inhibitors using a recombinant Escherichia coli , its validation and demonstration of Pistacia atlantica methanolic extract effectivity and specificity. Journal of Microbiological Methods 2017;133:40-5. [DOI: 10.1016/j.mimet.2016.11.022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
32 Gweon TG, Kim JS, Kim BW. An Economic Modeling Study of Helicobacter pylori Eradication: Comparison of Dual Priming Oligonucleotide-Based Multiplex Polymerase Chain Reaction and Empirical Treatment. Gut Liver 2018;12:648-54. [PMID: 30037167 DOI: 10.5009/gnl18079] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 8.5] [Reference Citation Analysis]
33 Dore MP, Cuccu M, Pes GM, Manca A, Graham DY. Lactobacillus reuteri in the treatment of Helicobacter pylori infection. Intern Emerg Med. 2014;9:649-654. [PMID: 24178436 DOI: 10.1007/s11739-013-1013-z] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
34 Rodríguez de Santiago E, Martín de Argila de Prados C, Marcos Prieto HM, Jorge Turrión MÃ, Barreiro Alonso E, Flores de Miguel A, de la Coba Ortiz C, Rodríguez Escaja C, Pérez Álvarez G, Ferre Aracil C, Aguilera Castro L, García García de Paredes A, Rodríguez Pérez A, Albillos Martínez A. Limited effectiveness with a 10-day bismuth-containing quadruple therapy (Pylera ® ) in third-line recue treatment for Helicobacter pylori infection. A real-life multicenter study. Helicobacter 2017;22:e12423. [DOI: 10.1111/hel.12423] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
35 Fallone CA, Moss SF, Malfertheiner P. Reconciliation of recent Helicobacter pylori treatment guidelines in a time of increasing resistance to antibiotics. Gastroenterology. 2019;157:44-53. [PMID: 30998990 DOI: 10.1053/j.gastro.2019.04.011] [Cited by in Crossref: 90] [Cited by in F6Publishing: 63] [Article Influence: 45.0] [Reference Citation Analysis]
36 Oikawa R, Watanabe Y, Miyamoto S, Sato Y, Ono S, Mabe K, Yamamoto H, Kato M, Itoh F. Enrichment of Helicobacter pylori mutant strains after eradication therapy analyzed by gastric wash-based quantitative pyrosequencing. Tumour Biol 2017;39:1010428317734865. [PMID: 28990461 DOI: 10.1177/1010428317734865] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
37 Raaf N, Amhis W, Saoula H, Abid A, Nakmouche M, Balamane A, Ali Arous N, Ouar-Korichi M, Vale FF, Bénéjat L, Mégraud F. Prevalence, antibiotic resistance, and MLST typing of Helicobacter pylori in Algiers, Algeria. Helicobacter 2017;22. [PMID: 29035009 DOI: 10.1111/hel.12446] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
38 Yoon K, Kim N, Lee JW, Yoon H, Shin CM, Park YS, Lee DH. Annual eradication rate of bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: A 15-year prospective study at a tertiary hospital in Korea. Helicobacter. 2020;25:e12685. [PMID: 32141173 DOI: 10.1111/hel.12685] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
39 Feng L, Wen MY, Zhu YJ, Men RT, Yang L. Sequential Therapy or Standard Triple Therapy for Helicobacter pylori Infection: An Updated Systematic Review. Am J Ther. 2016;23:e880-e893. [PMID: 25569598 DOI: 10.1097/mjt.0000000000000191] [Cited by in Crossref: 22] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
40 Mégraud F, Alix C, Charron P, Bénéjat L, Ducournau A, Bessède E, Lehours P. Survey of the antimicrobial resistance of Helicobacter pylori in France in 2018 and evolution during the previous 5 years. Helicobacter 2021;26:e12767. [PMID: 33090614 DOI: 10.1111/hel.12767] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Bricker-Ford R. Novel "High-dose Quad" Salvage Therapy Approach for Helicobacter pylori Infection: A Case Report. J Pharm Pract 2021;:8971900211033143. [PMID: 34269127 DOI: 10.1177/08971900211033143] [Reference Citation Analysis]
42 Siow JYM, Chan A, Østbye T, Cheng GH, Malhotra R. Validity and Reliability of the Positive Aspects of Caregiving (PAC) Scale and Development of Its Shorter Version (S-PAC) Among Family Caregivers of Older Adults. GERONT. [DOI: 10.1093/geront/gnw198] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
43 Hu Y, Zhu Y, Lu NH. Novel and Effective Therapeutic Regimens for Helicobacter pylori in an Era of Increasing Antibiotic Resistance. Front Cell Infect Microbiol 2017;7:168. [PMID: 28529929 DOI: 10.3389/fcimb.2017.00168] [Cited by in Crossref: 47] [Cited by in F6Publishing: 33] [Article Influence: 11.8] [Reference Citation Analysis]
44 Chen Q, Zhang W, Fu Q, Liang X, Liu W, Xiao S, Lu H. Rescue Therapy for Helicobacter pylori Eradication: A Randomized Non-Inferiority Trial of Amoxicillin or Tetracycline in Bismuth Quadruple Therapy. American Journal of Gastroenterology 2016;111:1736-42. [DOI: 10.1038/ajg.2016.443] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 8.4] [Reference Citation Analysis]
45 Kwon YH, Kim N, Lee JY, Choi YJ, Yoon K, Nam RH, Suh JH, Lee JW, Lee DH. Comparison of the efficacy of culture-based tailored therapy for Helicobacter pylori eradication with that of the traditional second-line rescue therapy in Korean patients: a prospective single tertiary center study. Scand J Gastroenterol. 2016;51:270-276. [PMID: 26452405 DOI: 10.3109/00365521.2015.1095352] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
46 Cammarota G, Ianiro G, Bibbò S, Di Rienzo TA, Masucci L, Sanguinetti M, Gasbarrini A. Culture-guided treatment approach for Helicobacter pylori infection: review of the literature. World J Gastroenterol. 2014;20:5205-5211. [PMID: 24833850 DOI: 10.3748/wjg.v20.i18.5205] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
47 Miehlke S, Frederking D, Günther T, Glocker E, Eisele B, Andresen V, Schröder S, Morgner A. Efficacy of three-in-one capsule bismuth quadruple therapy for Helicobacter pylori eradication in clinical practice in a multinational patient population. Helicobacter 2017;22:e12429. [DOI: 10.1111/hel.12429] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
48 Kocsmár É, Buzás GM, Szirtes I, Kocsmár I, Kramer Z, Szijártó A, Fadgyas-Freyler P, Szénás K, Rugge M, Fassan M, Kiss A, Schaff Z, Röst G, Lotz G. Primary and secondary clarithromycin resistance in Helicobacter pylori and mathematical modeling of the role of macrolides. Nat Commun 2021;12:2255. [PMID: 33859206 DOI: 10.1038/s41467-021-22557-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
49 Gisbert JP. Empirical or susceptibility-guided treatment for Helicobacter pylori infection? Therap Adv Gastroenterol. 2020;13:1756284820968736. [PMID: 33240392 DOI: 10.1177/1756284820968736] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
50 Kocsmár É, Kocsmár I, Buzás GM, Szirtes I, Wacha J, Takáts A, Hritz I, Schaff Z, Rugge M, Fassan M, Kiss A, Lotz G. Helicobacter pylori heteroresistance to clarithromycin in adults-New data by in situ detection and improved concept. Helicobacter 2020;25:e12670. [PMID: 31701608 DOI: 10.1111/hel.12670] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
51 Cerqueira L, Fernandes RM, Ferreira RM, Oleastro M, Carneiro F, Brandão C, Pimentel-Nunes P, Dinis-Ribeiro M, Figueiredo C, Keevil CW, Vieira MJ, Azevedo NF. Validation of a fluorescence in situ hybridization method using peptide nucleic acid probes for detection of Helicobacter pylori clarithromycin resistance in gastric biopsy specimens. J Clin Microbiol 2013;51:1887-93. [PMID: 23596234 DOI: 10.1128/JCM.00302-13] [Cited by in Crossref: 31] [Cited by in F6Publishing: 15] [Article Influence: 3.9] [Reference Citation Analysis]
52 Sisay Zewdu W, Jemere Aragaw T. Evaluation of the Anti-Ulcer Activity of Hydromethanolic Crude Extract and Solvent Fractions of the Root of Rumex nepalensis in Rats. J Exp Pharmacol 2020;12:325-37. [PMID: 33061674 DOI: 10.2147/JEP.S258586] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
53 Papaefthymiou A, Liatsos C, Georgopoulos SD, Apostolopoulos P, Doulberis M, Kyriakos N, Giakoumis M, Papadomichelakis M, Galanopoulos M, Katsinelos P, Rokkas T, Kountouras J. Helicobacter pylori eradication regimens in an antibiotic high-resistance European area: A cost-effectiveness analysis. Helicobacter 2020;25:e12666. [PMID: 31692137 DOI: 10.1111/hel.12666] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
54 Taha-Mehlitz S, Mongelli F, Sykora M, Scheiwiller A, Diebold J, Metzger J, Gass JM. Routine histopathologic examination of the resected specimen after laparoscopic sleeve gastrectomy - what can be expected? Acta Chir Belg 2020;:1-6. [PMID: 32644013 DOI: 10.1080/00015458.2020.1794335] [Reference Citation Analysis]
55 Kale-Pradhan PB, Mihaescu A, Wilhelm SM. Fluoroquinolone Sequential Therapy for Helicobacter pylori: A Meta-analysis. Pharmacotherapy. 2015;35:719-730. [PMID: 26173786 DOI: 10.1002/phar.1614] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
56 De Francesco V, Bellesia A, Ridola L, Manta R, Zullo A. First-line therapies for Helicobacter pylori eradication: a critical reappraisal of updated guidelines. Ann Gastroenterol. 2017;30:373-379. [PMID: 28655973 DOI: 10.20524/aog.2017.0166] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
57 Mărginean CO, Meliț LE, Săsăran MO. Gastric Microenvironment-A Partnership between Innate Immunity and Gastric Microbiota Tricks Helicobacter pylori. J Clin Med 2021;10:3258. [PMID: 34362042 DOI: 10.3390/jcm10153258] [Reference Citation Analysis]
58 Yi DM, Yang TT, Chao SH, Li YX, Zhou YL, Zhang HH, Lan L, Zhang YW, Wang XM, Zhang YR, Li J, Ding SZ. Comparison the cost-efficacy of furazolidone-based versus clarithromycin-based quadruple therapy in initial treatment of Helicobacter pylori infection in a variable clarithromycin drug-resistant region, a single-center, prospective, randomized, open-label study. Medicine (Baltimore) 2019;98:e14408. [PMID: 30732192 DOI: 10.1097/MD.0000000000014408] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
59 Brennan DE, Dowd C, O'Morain C, McNamara D, Smith SM. Can bacterial virulence factors predict antibiotic resistant Helicobacter pylori infection? World J Gastroenterol 2018;24:971-81. [PMID: 29531461 DOI: 10.3748/wjg.v24.i9.971] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
60 Guo L, Yin R, Liu K, Lv X, Li Y, Duan X, Chu Y, Xi T, Xing Y. Immunological features and efficacy of a multi-epitope vaccine CTB-UE against H. pylori in BALB/c mice model. Appl Microbiol Biotechnol 2014;98:3495-507. [DOI: 10.1007/s00253-013-5408-6] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 3.9] [Reference Citation Analysis]
61 Liou JM, Lee YC, Wu MS. Treatment of Helicobacter pylori infection and its long-term impacts on gut microbiota. J Gastroenterol Hepatol 2020;35:1107-16. [PMID: 31984532 DOI: 10.1111/jgh.14992] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
62 Sugimoto M, Sahara S, Ichikawa H, Kagami T, Ban H, Otsuka T, Andoh A, Furuta T. Four-times-daily Dosing of Rabeprazole with Sitafloxacin, High-Dose Amoxicillin, or Both for Metronidazole-Resistant Infection with Helicobacter pylori in Japan. Helicobacter. 2017;22. [PMID: 27213463 DOI: 10.1111/hel.12319] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
63 Fasciana T, Calà C, Bonura C, Di Carlo E, Matranga D, Scarpulla G, Manganaro M, Camilleri S, Giammanco A. Resistance to clarithromycin and genotypes in Helicobacter pylori strains isolated in Sicily. J Med Microbiol 2015;64:1408-14. [PMID: 26338221 DOI: 10.1099/jmm.0.000163] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
64 Pilotto A, Franceschi M. Helicobacter pylori infection in older people. World J Gastroenterol. 2014;20:6364-6373. [PMID: 24914358 DOI: 10.3748/wjg.v20.i21.6364] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
65 Jiang M, Ma L, Huang Y, Wu H, Dou J, Zhou C. Antimicrobial activities of peptide Cbf-K16 against drug-resistant Helicobacter pylori infection in vitro and in vivo. Microb Pathog 2020;138:103847. [PMID: 31704464 DOI: 10.1016/j.micpath.2019.103847] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
66 Keikha M, Eslami M, Yousefi B, Ghasemian A, Karbalaei M. Potential antigen candidates for subunit vaccine development against Helicobacter pylori infection. J Cell Physiol 2019;234:21460-70. [DOI: 10.1002/jcp.28870] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 10.0] [Reference Citation Analysis]
67 Seo JW, Park JY, Shin TS, Kim JG. The analysis of virulence factors and antibiotic resistance between Helicobacter pylori strains isolated from gastric antrum and body. BMC Gastroenterol 2019;19:140. [PMID: 31390989 DOI: 10.1186/s12876-019-1062-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
68 Iqbal U, Khara HS, Akhtar D, Hu Y, Anwar H, Haq KF, Siddiqui HU, Bergenstock MK, Shellenberger MJ. Safety and Efficacy of Nitazoxanide-Based Regimen for the Eradication of Helicobacter pylori Infection: A Systematic Review and Meta-Analysis. Gastroenterology Res 2020;13:260-8. [PMID: 33447305 DOI: 10.14740/gr1342] [Reference Citation Analysis]
69 Peretz A, Paritsky M, Dinisman-Zavulunov E, Pastukh N, Glyatman T, On A. Susceptibility of Helicobacter pylori to Levofloxacin and Rifampicin in Israel. Microb Drug Resist 2015;21:448-51. [PMID: 25793253 DOI: 10.1089/mdr.2014.0250] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
70 Gisbert JP. Optimization Strategies Aimed to Increase the Efficacy of Helicobacter pylori Eradication Therapies with Quinolones. Molecules 2020;25:E5084. [PMID: 33147814 DOI: 10.3390/molecules25215084] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
71 Alarcón T, Urruzuno P, Martínez MJ, Domingo D, Llorca L, Correa A, López-brea M. Antimicrobial susceptibility of 6 antimicrobial agents in Helicobacter pylori clinical isolates by using EUCAST breakpoints compared with previously used breakpoints. Enfermedades Infecciosas y Microbiología Clínica 2017;35:278-82. [DOI: 10.1016/j.eimc.2016.02.010] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
72 Apostolopoulos P, Koumoutsos I, Ekmektzoglou K, Dogantzis P, Vlachou E, Kalantzis C, Tsibouris P, Alexandrakis G. Concomitant versus sequential therapy for the treatment of Helicobacter pylori infection: a Greek randomized prospective study. Scand J Gastroenterol. 2016;51:145-151. [PMID: 26435055 DOI: 10.3109/00365521.2015.1079646] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
73 Fernández-Reyes M, Tamayo E, Rojas-Rengifo D, Fischer W, Carrasco-García E, Alonso M, Lizasoain J, Bujanda L, Cosme Á, Montes M. Helicobacter pylori pathogenicity and primary antimicrobial resistance in Northern Spain. Eur J Clin Invest 2019;49:e13150. [PMID: 31192451 DOI: 10.1111/eci.13150] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
74 Shield KD, Marant Micallef C, de Martel C, Heard I, Megraud F, Plummer M, Vignat J, Bray F, Soerjomataram I. New cancer cases in France in 2015 attributable to infectious agents: a systematic review and meta-analysis. Eur J Epidemiol 2018;33:263-74. [DOI: 10.1007/s10654-017-0334-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
75 Pichon M, Pichard B, Barrioz T, Plouzeau C, Croquet V, Fotsing G, Chéron A, Vuillemin É, Wangermez M, Haineaux PA, Vasseur P, Thiebault Q, Lefèvre C, de Singly A, Cremniter J, Broutin L, Michaud A, Silvain C, Burucoa C. Diagnostic Accuracy of a Noninvasive Test for Detection of Helicobacter pylori and Resistance to Clarithromycin in Stool by the Amplidiag H. pylori+ClariR Real-Time PCR Assay. J Clin Microbiol 2020;58:e01787-19. [PMID: 31996442 DOI: 10.1128/JCM.01787-19] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 17.0] [Reference Citation Analysis]
76 Sheu BS, Wu MS, Chiu CT, Lo JC, Wu DC, Liou JM, Wu CY, Cheng HC, Lee YC, Hsu PI, Chang CC, Chang WL, Lin JT. Consensus on the clinical management, screening-to-treat, and surveillance of Helicobacter pylori infection to improve gastric cancer control on a nationwide scale. Helicobacter. 2017;22. [PMID: 28066960 DOI: 10.1111/hel.12368] [Cited by in Crossref: 40] [Cited by in F6Publishing: 32] [Article Influence: 10.0] [Reference Citation Analysis]
77 Selgrad M, Malfertheiner P. Management of Helicobacter pylori Infection: What Should the Surgeon Know? Visc Med 2017;33:216-9. [PMID: 28785571 DOI: 10.1159/000477977] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
78 Selgrad M, Tammer I, Langner C, Bornschein J, Meißle J, Kandulski A, Varbanova M, Wex T, Schlüter D, Malfertheiner P. Different antibiotic susceptibility between antrum and corpus of the stomach, a possible reason for treatment failure of Helicobacter pylori infection. World J Gastroenterol 2014;20:16245-51. [PMID: 25473179 DOI: 10.3748/wjg.v20.i43.16245] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 30] [Article Influence: 6.3] [Reference Citation Analysis]
79 Liou JM, Chen PY, Kuo YT, Wu MS; Taiwan Gastrointestinal Disease and Helicobacter Consortium. Toward population specific and personalized treatment of Helicobacter pylori infection. J Biomed Sci 2018;25:70. [PMID: 30285834 DOI: 10.1186/s12929-018-0471-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
80 Calvet X. Dealing with uncertainty in the treatment of Helicobacter pylori. Ther Adv Chronic Dis 2018;9:93-102. [PMID: 29623181 DOI: 10.1177/2040622318758240] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
81 Ermis F, Senocak Tasci E. Current Helicobacter pylori treatment in 2014. World J Methodol 2015;5:101-7. [PMID: 26140276 DOI: 10.5662/wjm.v5.i2.101] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
82 Cammarota G, Ianiro G, Bibbò S, Gasbarrini A. Gut microbiota modulation: probiotics, antibiotics or fecal microbiota transplantation? Intern Emerg Med. 2014;9:365-373. [PMID: 24664520 DOI: 10.1007/s11739-014-1069-4] [Cited by in Crossref: 63] [Cited by in F6Publishing: 53] [Article Influence: 9.0] [Reference Citation Analysis]
83 Alarcón T, José Martínez-Gómez M, Urruzuno P. Helicobacter pylori in pediatrics. Helicobacter 2013;18 Suppl 1:52-7. [PMID: 24011246 DOI: 10.1111/hel.12070] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
84 Narayana JL, Huang HN, Wu CJ, Chen JY. Epinecidin-1 antimicrobial activity: In vitro membrane lysis and In vivo efficacy against Helicobacter pylori infection in a mouse model. Biomaterials. 2015;61:41-51. [PMID: 25996410 DOI: 10.1016/j.biomaterials.2015.05.014] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 4.7] [Reference Citation Analysis]
85 . UEG Week 2016 Poster Presentations. United European Gastroenterology Journal 2016;4:A157-720. [DOI: 10.1177/2050640616663689] [Cited by in Crossref: 14] [Cited by in F6Publishing: 3] [Article Influence: 2.8] [Reference Citation Analysis]
86 Almeida N, Romãozinho JM, Donato MM, Luxo C, Cardoso O, Cipriano MA, Marinho C, Sofia C. Triple therapy with high-dose proton-pump inhibitor, amoxicillin, and doxycycline is useless for Helicobacter pylori eradication: a proof-of-concept study. Helicobacter 2014;19:90-7. [PMID: 24506175 DOI: 10.1111/hel.12106] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
87 Graham DY. Illusions regarding Helicobacter pylori clinical trials and treatment guidelines. Gut 2017;66:2043-6. [PMID: 28935677 DOI: 10.1136/gutjnl-2017-314744] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
88 Graham DY, Lee YC, Wu MS. Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. Clin Gastroenterol Hepatol. 2014;12:177-186.e3; Discussion e12-e13. [PMID: 23751282 DOI: 10.1016/j.cgh.2013.05.028] [Cited by in Crossref: 195] [Cited by in F6Publishing: 161] [Article Influence: 24.4] [Reference Citation Analysis]
89 Nkuize M, Vanderpas J, Buset M, Gomez-Galdon M, Delforge M, Miendje-Deyi VY, Muls V, De Wit S. Primary antibiotic resistance of Helicobacter pylori isolates is twofold more frequent in HIV-positive than HIV-negative individuals: A descriptive observational study. Microbiologyopen 2021;10:e1184. [PMID: 34180600 DOI: 10.1002/mbo3.1184] [Reference Citation Analysis]
90 Shokrzadeh L, Alebouyeh M, Mirzaei T, Farzi N, Zali MR. Prevalence of multiple drug-resistant Helicobacter pylori strains among patients with different gastric disorders in Iran. Microb Drug Resist. 2015;21:105-110. [PMID: 25303151 DOI: 10.1089/mdr.2014.0081] [Cited by in Crossref: 22] [Cited by in F6Publishing: 11] [Article Influence: 3.1] [Reference Citation Analysis]
91 Ciccaglione AF, Cellini L, Marzio L. Pylera® plus ranitidine vs Pylera® plus esomeprazole in first‐line treatment of Helicobacter pylori infection: Two pilot studies. Helicobacter 2019;24. [DOI: 10.1111/hel.12606] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
92 Spiteri JA, Zahra G, Schembri J, Pisani A, Borg E, Spiteri N, Bianco EZ, Caruana P, Gauci J, Muscat M, Barbara C, Ellul P. Identification of antibiotic resistance patterns in Helicobacter pylori strains isolated from gastric biopsies using real-time PCR and genotypic analysis. Ann Gastroenterol 2021;34:501-9. [PMID: 34276188 DOI: 10.20524/aog.2021.0624] [Reference Citation Analysis]
93 Shiota S, Reddy R, Alsarraj A, El-Serag HB, Graham DY. Antibiotic Resistance of Helicobacter pylori Among Male United States Veterans. Clin Gastroenterol Hepatol. 2015;13:1616-1624. [PMID: 25681693 DOI: 10.1016/j.cgh.2015.02.005] [Cited by in Crossref: 93] [Cited by in F6Publishing: 73] [Article Influence: 15.5] [Reference Citation Analysis]
94 Gisbert JP, Romano M, Molina-Infante J, Lucendo AJ, Medina E, Modolell I, Rodríguez-Tellez M, Gomez B, Barrio J, Perona M. Two-week, high-dose proton pump inhibitor, moxifloxacin triple Helicobacter pylori therapy after failure of standard triple or non-bismuth quadruple treatments. Dig Liver Dis. 2015;47:108-113. [PMID: 25454706 DOI: 10.1016/j.dld.2014.10.009] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
95 Blum FC, Singh J, Merrell DS. In vitro activity of neem (Azadirachta indica) oil extract against Helicobacter pylori. J Ethnopharmacol 2019;232:236-43. [PMID: 30578933 DOI: 10.1016/j.jep.2018.12.025] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
96 Lawson AJ. Helicobacter. In: Jorgensen JH, Carroll KC, Funke G, Pfaller MA, Landry ML, Richter SS, Warnock DW, editors. Manual of Clinical Microbiology. Washington: ASM Press; 2015. pp. 1013-27. [DOI: 10.1128/9781555817381.ch57] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
97 Bang CS, Baik GH. Attempts to enhance the eradication rate of Helicobacter pylori infection. World J Gastroenterol. 2014;20:5252-5262. [PMID: 24833855 DOI: 10.3748/wjg.v20.i18.5252] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
98 Mégraud F. Current recommendations for Helicobacter pylori therapies in a world of evolving resistance. Gut Microbes. 2013;4:541-548. [PMID: 23929066 DOI: 10.4161/gmic.25930] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.4] [Reference Citation Analysis]
99 Yeo YH, Shiu SI, Ho HJ, Zou B, Lin JT, Wu MS, Liou JM, Wu CY; Taiwan Gastrointestinal Disease and Helicobacter Consortium. First-line Helicobacter pylori eradication therapies in countries with high and low clarithromycin resistance: a systematic review and network meta-analysis. Gut. 2018;67:20-27. [PMID: 27670375 DOI: 10.1136/gutjnl-2016-311868] [Cited by in Crossref: 42] [Cited by in F6Publishing: 31] [Article Influence: 8.4] [Reference Citation Analysis]
100 Muñoz N, Sánchez-Delgado J, Baylina M, López-Góngora S, Calvet X. Prevalence of Helicobacter pylori resistance after failure of first-line therapy. A systematic review. Gastroenterol Hepatol 2018;41:654-62. [PMID: 30180998 DOI: 10.1016/j.gastrohep.2018.06.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
101 Verma A, Dubey J, Hegde RR, Rastogi V, Pandit JK. Helicobacter pylori : past, current and future treatment strategies with gastroretentive drug delivery systems. Journal of Drug Targeting 2016;24:897-915. [DOI: 10.3109/1061186x.2016.1171326] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
102 Guiard E, Lelievre B, Rouyer M, Zerbib F, Diquet B, Mégraud F, Tison F, Bignon E, Lassalle R, Droz-Perroteau C, Moore N, Blin P. Bismuth Concentrations in Patients Treated in Real-Life Practice with a Bismuth Subcitrate-Metronidazole-Tetracycline Preparation: The SAPHARY Study. Drug Saf 2019;42:993-1003. [PMID: 31069703 DOI: 10.1007/s40264-019-00821-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
103 Shokri-shirvani J, Zamani V, Zamani M. Letter: global emergence of Helicobacter pylori antibiotic resistance - unanswered questions. Aliment Pharmacol Ther 2016;43:1249-1249. [DOI: 10.1111/apt.13612] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
104 Krzyżek P, Pawełka D, Iwańczak B, Kempiński R, Leśniakowski K, Mégraud F, Łaczmański Ł, Biernat M, Gościniak G. High Primary Antibiotic Resistance of Helicobacter pylori Strains Isolated from Pediatric and Adult Patients in Poland during 2016-2018. Antibiotics (Basel) 2020;9:E228. [PMID: 32370201 DOI: 10.3390/antibiotics9050228] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
105 De Francesco V, Zullo A, Fiorini G, Saracino IM, Pavoni M, Vaira D. Role of MIC levels of resistance to clarithromycin and metronidazole in Helicobacter pylori eradication. Journal of Antimicrobial Chemotherapy 2019;74:772-4. [DOI: 10.1093/jac/dky469] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
106 Hathroubi S, Zerebinski J, Clarke A, Ottemann KM. Helicobacter pylori Biofilm Confers Antibiotic Tolerance in Part via A Protein-Dependent Mechanism. Antibiotics (Basel) 2020;9:E355. [PMID: 32599828 DOI: 10.3390/antibiotics9060355] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
107 Guo B, Cao NW, Zhou HY, Chu XJ, Li BZ. Efficacy and safety of bismuth-containing quadruple treatment and concomitant treatment for first-line Helicobacter pylori eradication: A systematic review and meta-analysis. Microb Pathog 2021;152:104661. [PMID: 33249167 DOI: 10.1016/j.micpath.2020.104661] [Reference Citation Analysis]
108 Liou JM, Fang YJ, Chen CC, Bair MJ, Chang CY, Lee YC, Chen MJ, Chen CC, Tseng CH, Hsu YC, Lee JY, Yang TH, Luo JC, Chang CC, Chen CY, Chen PY, Shun CT, Hsu WF, Hu WH, Chen YN, Sheu BS, Lin JT, Wu JY, El-Omar EM, Wu MS; Taiwan Gastrointestinal Disease and Helicobacter Consortium. Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. Lancet. 2016;388:2355-2365. [PMID: 27769562 DOI: 10.1016/s0140-6736(16)31409-x] [Cited by in Crossref: 74] [Cited by in F6Publishing: 21] [Article Influence: 14.8] [Reference Citation Analysis]
109 Saracino IM, Fiorini G, Zullo A, Pavoni M, Saccomanno L, Vaira D. Trends in Primary Antibiotic Resistance in H. pylori Strains Isolated in Italy between 2009 and 2019. Antibiotics (Basel) 2020;9:E26. [PMID: 31941121 DOI: 10.3390/antibiotics9010026] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 10.0] [Reference Citation Analysis]
110 Tseng Y, Liou J, Hsu T, Cheng W, Wu M, Wong C. Development of bacterial transglycosylase inhibitors as new antibiotics: Moenomycin A treatment for drug-resistant Helicobacter pylori. Bioorganic & Medicinal Chemistry Letters 2014;24:2412-4. [DOI: 10.1016/j.bmcl.2014.04.041] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
111 Yang JC, Lu CW, Lin CJ. Treatment of Helicobacter pylori infection: current status and future concepts. World J Gastroenterol. 2014;20:5283-5293. [PMID: 24833858 DOI: 10.3748/wjg.v20.i18.5283] [Cited by in CrossRef: 61] [Cited by in F6Publishing: 42] [Article Influence: 10.2] [Reference Citation Analysis]
112 Biernat MM, Wróbel T. Bacterial Infection and Non-Hodgkin B-Cell Lymphoma: Interactions between Pathogen, Host and the Tumor Environment. Int J Mol Sci 2021;22:7372. [PMID: 34298992 DOI: 10.3390/ijms22147372] [Reference Citation Analysis]
113 Park JY, Forman D, Waskito LA, Yamaoka Y, Crabtree JE. Epidemiology of Helicobacter pylori and CagA-Positive Infections and Global Variations in Gastric Cancer. Toxins (Basel). 2018;10:pii: E163. [PMID: 29671784 DOI: 10.3390/toxins10040163] [Cited by in Crossref: 57] [Cited by in F6Publishing: 36] [Article Influence: 19.0] [Reference Citation Analysis]
114 Ergül B, Doğan Z, Sarikaya M, Filik L. The efficacy of two-week quadruple first-line therapy with bismuth, lansoprazole, amoxicillin, clarithromycin on Helicobacter pylori eradication: a prospective study. Helicobacter 2013;18:454-8. [PMID: 24011287 DOI: 10.1111/hel.12086] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
115 Lopo I, Libânio D, Pita I, Dinis-ribeiro M, Pimentel-nunes P. Helicobacter pylori antibiotic resistance in Portugal: Systematic review and meta-analysis. Helicobacter 2018;23:e12493. [DOI: 10.1111/hel.12493] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
116 Nyssen OP, McNicholl AG, Megraud F, Savarino V, Oderda G, Fallone CA, Fischbach L, Bazzoli F, Gisbert JP. Sequential versus standard triple first-line therapy for Helicobacter pylori eradication. Cochrane Database Syst Rev 2016;:CD009034. [PMID: 27351542 DOI: 10.1002/14651858.CD009034.pub2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
117 Fallone CA, Chiba N, van Zanten SV, Fischbach L, Gisbert JP, Hunt RH, Jones NL, Render C, Leontiadis GI, Moayyedi P, Marshall JK. The Toronto consensus for the treatment of Helicobacter pylori infection in adults. Gastroenterology. 2016;151:51-69.e14. [PMID: 27102658 DOI: 10.1053/j.gastro.2016.04.006] [Cited by in Crossref: 362] [Cited by in F6Publishing: 263] [Article Influence: 72.4] [Reference Citation Analysis]
118 Fiorini G, Saracino IM, Zullo A, Gatta L, Pavoni M, Vaira D. Rescue therapy with bismuth quadruple regimen in patients with Helicobacter pylori -resistant strains. Helicobacter 2017;22:e12448. [DOI: 10.1111/hel.12448] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
119 Smith S, Boyle B, Brennan D, Buckley M, Crotty P, Doyle M, Farrell R, Hussey M, Kevans D, Malfertheiner P. The Irish Helicobacter pylori Working Group consensus for the diagnosis and treatment of H. pylori infection in adult patients in Ireland. Eur J Gastroenterol Hepatol. 2017;29:552-559. [PMID: 28350745 DOI: 10.1097/meg.0000000000000822] [Cited by in Crossref: 20] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
120 Caliskan R, Tokman HB, Erzin Y, Saribas S, Yuksel P, Bolek BK, Sevuk EO, Demirci M, Yılmazli O, Akgul O, Kalayci F, Cakan H, Salih B, Bal K, Kocazeybek B. Antimicrobial resistance of Helicobacter pylori strains to five antibiotics, including levofloxacin, in Northwestern Turkey. Rev Soc Bras Med Trop 2015;48:278-84. [PMID: 26108005 DOI: 10.1590/0037-8682-0027-2015] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 5.8] [Reference Citation Analysis]
121 Singh SP, Ahuja V, Ghoshal UC, Makharia G, Dutta U, Zargar SA, Venkataraman J, Dutta AK, Mukhopadhyay AK, Singh A, Thapa BR, Vaiphei K, Sathiyasekaran M, Sahu MK, Rout N, Abraham P, Dalai PC, Rathi P, Sinha SK, Bhatia S, Patra S, Ghoshal U, Poddar U, Mouli VP, Kate V. Management of Helicobacter pylori infection: The Bhubaneswar Consensus Report of the Indian Society of Gastroenterology. Indian J Gastroenterol 2021. [PMID: 34219211 DOI: 10.1007/s12664-021-01186-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
122 Lee H, Hong SN, Min BH, Lee JH, Rhee PL, Lee YC, Kim JJ. Comparison of efficacy and safety of levofloxacin-containing versus standard sequential therapy in eradication of Helicobacter pylori infection in Korea. Dig Liver Dis. 2015;47:114-118. [PMID: 25467826 DOI: 10.1016/j.dld.2014.10.014] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 2.1] [Reference Citation Analysis]
123 Malfertheiner P, Selgrad M, Wex T, Romi B, Borgogni E, Spensieri F, Zedda L, Ruggiero P, Pancotto L, Censini S, Palla E, Kanesa-thasan N, Scharschmidt B, Rappuoli R, Graham DY, Schiavetti F, Del Giudice G. Efficacy, immunogenicity, and safety of a parenteral vaccine against Helicobacter pylori in healthy volunteers challenged with a Cag-positive strain: a randomised, placebo-controlled phase 1/2 study. The Lancet Gastroenterology & Hepatology 2018;3:698-707. [DOI: 10.1016/s2468-1253(18)30125-0] [Cited by in Crossref: 23] [Cited by in F6Publishing: 8] [Article Influence: 7.7] [Reference Citation Analysis]
124 Abd-Elsalam S, Kobtan A, El-Kalla F, Elkhalawany W, Nawasany SE, Saif SA, Yousef M, Ali LA, Soliman S, Mansour L, Habba E, Soliman H, Rizk F, Shehata MA. A 2-week Nitazoxanide-based quadruple treatment as a rescue therapy for Helicobacter pylori eradication: A single center experience. Medicine (Baltimore) 2016;95:e3879. [PMID: 27310977 DOI: 10.1097/MD.0000000000003879] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 3.3] [Reference Citation Analysis]
125 Perkovic N, Mestrovic A, Bozic J, Ivelja MP, Vukovic J, Kardum G, Sundov Z, Tonkic M, Puljiz Z, Vukojevic K, Tonkic A. Randomized Clinical Trial Comparing Concomitant and Tailored Therapy for Eradication of Helicobacter pylori Infection. J Pers Med 2021;11:534. [PMID: 34207870 DOI: 10.3390/jpm11060534] [Reference Citation Analysis]
126 Zagari RM, Rabitti S, Eusebi LH, Bazzoli F. Treatment of Helicobacter pylori infection: A clinical practice update. Eur J Clin Invest. 2018;48. [PMID: 29144559 DOI: 10.1111/eci.12857] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 7.0] [Reference Citation Analysis]
127 Kuo YT, Liou JM, El-Omar EM, Wu JY, Leow AHR, Goh KL, Das R, Lu H, Lin JT, Tu YK. Primary antibiotic resistance in Helicobacter pylori in the Asia-Pacific region: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2017;2:707-715. [PMID: 28781119 DOI: 10.1016/s2468-1253(17)30219-4] [Cited by in Crossref: 96] [Cited by in F6Publishing: 34] [Article Influence: 24.0] [Reference Citation Analysis]
128 Hays C, Delerue T, Lamarque D, Burucoa C, Collobert G, Billöet A, Kalach N, Raymond J. Molecular diagnosis of Helicobacter pylori infection in gastric biopsies: Evaluation of the Amplidiag ®H. pylori  + ClariR assay. Helicobacter 2019;24:e12560. [DOI: 10.1111/hel.12560] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
129 Fong P, Wang QT. Protective effect of oral contraceptive against Helicobacter pylori infection in US adult females: NHANES 1999-2000. Epidemiol Infect 2021;149:e120. [PMID: 33896437 DOI: 10.1017/S0950268821000923] [Reference Citation Analysis]
130 Kanizaj TF, Kunac N. Helicobacter pylori: future perspectives in therapy reflecting three decades of experience. World J Gastroenterol. 2014;20:699-705. [PMID: 24574743 DOI: 10.3748/wjg.v20.i3.699] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 17] [Article Influence: 3.1] [Reference Citation Analysis]
131 Barahona-Garrido J, Quiñonez NF, Cerda-Contreras E, Maria Sarti H, Téllez-Ávila FI. Fosfomycin-containing second-line treatment for Helicobacter pylori infection. Am J Gastroenterol 2013;108:858-9. [PMID: 23644971 DOI: 10.1038/ajg.2013.48] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
132 Georgopoulos SD, Xirouchakis E, Martinez-Gonzales B, Zampeli E, Grivas E, Spiliadi C, Sotiropoulou M, Petraki K, Zografos K, Laoudi F. Randomized clinical trial comparing ten day concomitant and sequential therapies for Helicobacter pylori eradication in a high clarithromycin resistance area. Eur J Intern Med. 2016;32:84-90. [PMID: 27134145 DOI: 10.1016/j.ejim.2016.04.011] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 5.8] [Reference Citation Analysis]
133 Muller N, Amiot A, Le Thuaut A, Bastuji-garin S, Deforges L, Delchier J. Rescue therapy with bismuth-containing quadruple therapy in patients infected with metronidazole-resistant Helicobacter pylori strains. Clinics and Research in Hepatology and Gastroenterology 2016;40:517-24. [DOI: 10.1016/j.clinre.2015.12.012] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 6.4] [Reference Citation Analysis]
134 Wu JY, Hsu PI, Wu DC, Graham DY, Wang WM. Feasibility of shortening 14-day hybrid therapy while maintaining an excellent Helicobacter pylori eradication rate. Helicobacter. 2014;19:207-213. [PMID: 24612093 DOI: 10.1111/hel.12113] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
135 Miftahussurur M, Cruz M, Subsomwong P, Jiménez Abreu JA, Hosking C, Nagashima H, Akada J, Yamaoka Y. Clarithromycin-Based Triple Therapy is Still Useful as an Initial Treatment for Helicobacter pylori Infection in the Dominican Republic. Am J Trop Med Hyg 2017;96:1050-9. [PMID: 28193745 DOI: 10.4269/ajtmh.16-0729] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
136 Boltin D, Kimchi N, Dickman R, Gingold-Belfer R, Niv Y, Birkenfeld S. Attitudes and practice related to Helicobacter pylori infection among primary care physicians. Eur J Gastroenterol Hepatol 2016;28:1035-40. [PMID: 27167452 DOI: 10.1097/MEG.0000000000000659] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
137 Tamayo E, Montes M, Fernández-Reyes M, Lizasoain J, Ibarra B, Mendarte U, Zapata E, Mendiola J, Pérez-Trallero E. Clarithromycin resistance in Helicobacter pylori and its molecular determinants in Northern Spain, 2013-2015. J Glob Antimicrob Resist 2017;9:43-6. [PMID: 28343971 DOI: 10.1016/j.jgar.2016.12.019] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 4.5] [Reference Citation Analysis]
138 Dore MP, Lu H, Graham DY. Role of bismuth in improving Helicobacter pylori eradication with triple therapy. Gut. 2016;65:870-878. [PMID: 26848181 DOI: 10.1136/gutjnl-2015-311019] [Cited by in Crossref: 108] [Cited by in F6Publishing: 93] [Article Influence: 21.6] [Reference Citation Analysis]
139 Manfredi M, Gismondi P, Maffini V, Bizzarri B, Fornaroli F, Madia C, Salerno A, Cangelosi AM, de'Angelis GL. Primary Antimicrobial Susceptibility Changes in Children with Helicobacter pylori Infection over 13 Years in Northern Italy. Gastroenterol Res Pract 2015;2015:717349. [PMID: 26064096 DOI: 10.1155/2015/717349] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
140 Camorlinga-Ponce M, Gómez-Delgado A, Aguilar-Zamora E, Torres RC, Giono-Cerezo S, Escobar-Ogaz A, Torres J. Phenotypic and Genotypic Antibiotic Resistance Patterns in Helicobacter pylori Strains From Ethnically Diverse Population in México. Front Cell Infect Microbiol 2020;10:539115. [PMID: 33643927 DOI: 10.3389/fcimb.2020.539115] [Reference Citation Analysis]
141 Adriaenssens N, Bruyndonckx R, Versporten A, Hens N, Monnet DL, Molenberghs G, Goossens H, Weist K, Coenen S; ESAC-Net study group. Consumption of quinolones in the community, European Union/European Economic Area, 1997-2017. J Antimicrob Chemother 2021;76:ii37-44. [PMID: 34312652 DOI: 10.1093/jac/dkab176] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
142 Song M, Ang TL. Second and third line treatment options for Helicobacter pylori eradication. World J Gastroenterol. 2014;20:1517-1528. [PMID: 24587627 DOI: 10.3748/wjg.v20.i6.1517] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
143 Fiorini G, Zullo A, Saracino IM, Pavoni M, Vaira D. Antibiotic resistance pattern of Helicobacter pylori strains isolated in Italy during 2010–2016. Scandinavian Journal of Gastroenterology 2018;53:661-4. [DOI: 10.1080/00365521.2018.1464596] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
144 Almeida N, Donato MM, Romãozinho JM, Luxo C, Cardoso O, Cipriano MA, Marinho C, Fernandes A, Calhau C, Sofia C. Beyond Maastricht IV: are standard empiric triple therapies for Helicobacter pylori still useful in a South-European country? BMC Gastroenterol 2015;15:23. [PMID: 25886722 DOI: 10.1186/s12876-015-0245-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
145 Correia M, Michel V, Osório H, El Ghachi M, Bonis M, Boneca IG, De Reuse H, Matos AA, Lenormand P, Seruca R, Figueiredo C, Machado JC, Touati E. Crosstalk between Helicobacter pylori and gastric epithelial cells is impaired by docosahexaenoic acid.PLoS One. 2013;8:e60657. [PMID: 23577140 DOI: 10.1371/journal.pone.0060657] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
146 Mei H, Tu H. Vitamin C and Helicobacter pylori Infection: Current Knowledge and Future Prospects. Front Physiol 2018;9:1103. [PMID: 30154733 DOI: 10.3389/fphys.2018.01103] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
147 Nkuize M, De Wit S, Muls V, Delforge M, Miendje Deyi VY, Cadière GB, Buset M. HIV-Helicobacter pylori Co-Infection: Antibiotic Resistance, Prevalence, and Risk Factors. PLoS One 2015;10:e0145119. [PMID: 26691198 DOI: 10.1371/journal.pone.0145119] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
148 Gay N, Lugagne N, Miltgen G, Belmonte O, Cardinale E. Reunion Island, a sentinel territory for antimicrobial-resistant bacteria surveillance in the South-Western Indian Ocean: a retrospective survey using hospitalized patient screening, 2015-2017. BMC Public Health 2020;20:1488. [PMID: 33004028 DOI: 10.1186/s12889-020-09591-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
149 Garza-González E, Perez-Perez GI, Maldonado-Garza HJ, Bosques-Padilla FJ. A review of Helicobacter pylori diagnosis, treatment, and methods to detect eradication. World J Gastroenterol 2014;20:1438-49. [PMID: 24587620 DOI: 10.3748/wjg.v20.i6.1438] [Cited by in CrossRef: 86] [Cited by in F6Publishing: 69] [Article Influence: 14.3] [Reference Citation Analysis]
150 López-Góngora S, Puig I, Calvet X, Villoria A, Baylina M, Muñoz N, Sanchez-Delgado J, Suarez D, García-Hernando V, Gisbert JP. Systematic review and meta-analysis: susceptibility-guided versus empirical antibiotic treatment for Helicobacter pylori infection. J Antimicrob Chemother 2015;70:2447-55. [PMID: 26078393 DOI: 10.1093/jac/dkv155] [Cited by in Crossref: 76] [Cited by in F6Publishing: 65] [Article Influence: 12.7] [Reference Citation Analysis]
151 Sharara AI, Sarkis FS, El-Halabi MM, Malli A, Mansour NM, Azar C, Eloubeidi MA, Mourad FH, Barada K, Sukkarieh I. Challenging the dogma: a randomized trial of standard vs. half-dose concomitant nonbismuth quadruple therapy for Helicobacter pylori infection. United European Gastroenterol J 2014;2:179-88. [PMID: 25360301 DOI: 10.1177/2050640614530919] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
152 Kuo SH, Yeh KH, Wu MS, Lin CW, Wei MF, Liou JM, Wang HP, Chen LT, Cheng AL. First-line antibiotic therapy in Helicobacter pylori-negative low-grade gastric mucosa-associated lymphoid tissue lymphoma. Sci Rep 2017;7:14333. [PMID: 29084984 DOI: 10.1038/s41598-017-14102-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
153 Martins GM, Sanches BS, Moretzsohn LD, Lima KS, Cota BD, Coelho LG. Molecular detection of clarithromycin and fluoroquinolones resistance in Helicobacter pylori infection, directly applied to gastric biopsies, in an urban brazilian population. Arq Gastroenterol. 2016;53:113-117. [PMID: 27305419 DOI: 10.1590/s0004-28032016000200012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
154 Abu-Qatouseh L, Abu-Sini M, Mayyas A, Al-Hiari Y, Darwish R, Aburjai T. Synthesis of New Nitrofluoroquinolone Derivatives with Novel Anti-Microbial Properties against Metronidazole Resistant H. pylori. Molecules 2017;22:E71. [PMID: 28054994 DOI: 10.3390/molecules22010071] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
155 Kocazeybek B, Sakli MK, Yuksel P, Demirci M, Caliskan R, Sarp TZ, Saribas S, Demiryas S, Kalayci F, Cakan H, Uysal HK, Gareayaghi N, Ergin S, Erzin YZ, Bal K, Tascı İ, Tokman HB. Comparison of new and classical point mutations associated with clarithromycin resistance in Helicobacter pylori strains isolated from dyspeptic patients and their effects on phenotypic clarithromycin resistance. J Med Microbiol 2019;68:566-73. [PMID: 30724729 DOI: 10.1099/jmm.0.000944] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
156 Buzás GM. Benign and malignant gastroduodenal diseases associated with Helicobacter pylori: a narrative review and personal remarks in 2018. Minerva Gastroenterol Dietol 2018;64:280-96. [PMID: 29458240 DOI: 10.23736/S1121-421X.18.02481-9] [Cited by in Crossref: 24] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
157 Peek RM Jr. New Biology to New Treatment of Helicobacter pylori-Induced Gastric Cancer. Dig Dis 2016;34:510-6. [PMID: 27332886 DOI: 10.1159/000445231] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
158 Lee JY, Kim N, Park KS, Kim HJ, Park SM, Baik GH, Shim KN, Oh JH, Choi SC, Kim SE, Kim WH, Park SY, Kim GH, Lee BE, Jo Y, Hong SJ. Comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of Helicobacter pylori: a prospective, multi-center, randomized clinical trial. BMC Gastroenterol. 2016;16:79. [PMID: 27460100 DOI: 10.1186/s12876-016-0490-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
159 Camargo MC, García A, Riquelme A, Otero W, Camargo CA, Hernandez-García T, Candia R, Bruce MG, Rabkin CS. The problem of Helicobacter pylori resistance to antibiotics: a systematic review in Latin America. Am J Gastroenterol. 2014;109:485-495. [PMID: 24589670 DOI: 10.1038/ajg.2014.24] [Cited by in Crossref: 95] [Cited by in F6Publishing: 72] [Article Influence: 13.6] [Reference Citation Analysis]
160 Puig I, López-Góngora S, Calvet X, Villoria A, Baylina M, Sanchez-Delgado J, Suarez D, García-Hernando V, Gisbert JP. Systematic review: third-line susceptibility-guided treatment for Helicobacter pylori infection. Therap Adv Gastroenterol 2016;9:437-48. [PMID: 27366212 DOI: 10.1177/1756283X15621229] [Cited by in Crossref: 22] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
161 Long X, Chen Q, Yu L, Liang X, Liu W, Lu H. Bismuth improves efficacy of proton-pump inhibitor clarithromycin, metronidazole triple Helicobacter pylori therapy despite a high prevalence of antimicrobial resistance. Helicobacter 2018;23:e12485. [DOI: 10.1111/hel.12485] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 6.3] [Reference Citation Analysis]
162 Upala S, Sanguankeo A, Saleem SA, Jaruvongvanich V. Effects of Helicobacter pylori eradication on insulin resistance and metabolic parameters: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2017;29:153-159. [PMID: 27832037 DOI: 10.1097/meg.0000000000000774] [Cited by in Crossref: 19] [Cited by in F6Publishing: 6] [Article Influence: 4.8] [Reference Citation Analysis]
163 Kotilea K, Mekhael J, Salame A, Mahler T, Miendje-Deyi VY, Cadranel S, Bontems P. Eradication rate of Helicobacter Pylori infection is directly influenced by adherence to therapy in children. Helicobacter. 2017;22. [PMID: 28303625 DOI: 10.1111/hel.12383] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
164 Öztürk K, Kurt Ö, Çelebi G, Şarlak H, Karakaya MF, Demirci H, Kılınç A, Uygun A. High-dose dual therapy is effective as first-line treatment for Helicobacter pylori infection. Turk J Gastroenterol 2020;31:234-8. [PMID: 32343235 DOI: 10.5152/tjg.2020.18974] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
165 Serrano CA, Leon MA, Palma C, Vera M, Hernandez C, Harris PR. Helicobacter pylori-Clarithromycin Resistance in Symptomatic Pediatric Patients in a High Prevalence Country. Journal of Pediatric Gastroenterology & Nutrition 2017;64:e56-60. [DOI: 10.1097/mpg.0000000000001257] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
166 Ribaldone DG, Astegiano M, Saracco G, Pellicano R. Amoxycillin and Metronidazole Therapy for Helicobacter pylori Eradication: A 10-Year Trend in Turin, Italy. Balkan Med J 2017;34:290-1. [PMID: 28559221 DOI: 10.4274/balkanmedj.2015.1714] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
167 Brennan DE, Omorogbe J, Hussey M, Tighe D, Holleran G, O'Morain C, Smith SM, McNamara D. Molecular detection of Helicobacter pylori antibiotic resistance in stool vs biopsy samples. World J Gastroenterol. 2016;22:9214-9221. [PMID: 27895408 DOI: 10.3748/wjg.v22.i41.9214] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
168 Lv ZF, Wang FC, Zheng HL, Wang B, Xie Y, Zhou XJ, Lv NH. Meta-analysis: is combination of tetracycline and amoxicillin suitable for Helicobacter pylori infection? World J Gastroenterol. 2015;21:2522-2533. [PMID: 25741163 DOI: 10.3748/wjg.v21.i8.2522] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
169 Molina-Infante J, Gisbert JP. [Update on the efficacy of triple therapy for Helicobacter pylori infection and clarithromycin resistance rates in Spain (2007-2012)]. Gastroenterol Hepatol. 2013;36:375-381. [PMID: 23623461 DOI: 10.1016/j.gastrohep.2013.02.006] [Cited by in Crossref: 31] [Cited by in F6Publishing: 20] [Article Influence: 3.9] [Reference Citation Analysis]
170 Oporto M, Pavez M, Troncoso C, Cerda A, Hofmann E, Sierralta A, Rios E, Coppelli L, Barrientos L. Prevalence of Infection and Antibiotic Susceptibility of Helicobacter pylori: An Evaluation in Public and Private Health Systems of Southern Chile. Pathogens 2019;8:E226. [PMID: 31717523 DOI: 10.3390/pathogens8040226] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
171 Angol DC, Ocama P, Ayazika Kirabo T, Okeng A, Najjingo I, Bwanga F. Helicobacter pylori from Peptic Ulcer Patients in Uganda Is Highly Resistant to Clarithromycin and Fluoroquinolones: Results of the GenoType HelicoDR Test Directly Applied on Stool. Biomed Res Int. 2017;2017:5430723. [PMID: 28555193 DOI: 10.1155/2017/5430723] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
172 Leja M, Dumpis U. What Would the Screen-and-Treat Strategy for Helicobacter pylori Mean in Terms of Antibiotic Consumption? Dig Dis Sci 2020;65:1632-42. [PMID: 31659615 DOI: 10.1007/s10620-019-05893-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
173 Wu JY, Liou JM, Graham DY. Evidence-based recommendations for successful Helicobacter pylori treatment. Expert Rev Gastroenterol Hepatol. 2014;8:21-28. [PMID: 24410470 DOI: 10.1586/17474124.2014.859522] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 4.0] [Reference Citation Analysis]
174 Beermann S, Allerberger F, Wirtz A, Burger R, Hamouda O. Public health microbiology in Germany: 20 years of national reference centers and consultant laboratories. Int J Med Microbiol 2015;305:595-600. [PMID: 26321004 DOI: 10.1016/j.ijmm.2015.08.007] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
175 Fang HR, Zhang GQ, Cheng JY, Li ZY. Efficacy of Lactobacillus-supplemented triple therapy for Helicobacter pylori infection in children: a meta-analysis of randomized controlled trials.Eur J Pediatr. 2019;178:7-16. [PMID: 30446816 DOI: 10.1007/s00431-018-3282-z] [Cited by in Crossref: 26] [Cited by in F6Publishing: 17] [Article Influence: 8.7] [Reference Citation Analysis]
176 Gisbert JP, Molina-Infante J, Marin AC, Vinagre G, Barrio J, McNicholl AG. Second-line rescue triple therapy with levofloxacin after failure of non-bismuth quadruple "sequential" or "concomitant" treatment to eradicate H. pylori infection. Scand J Gastroenterol. 2013;48:652-656. [PMID: 23556551 DOI: 10.3109/00365521.2013.786132] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
177 Di Giulio M, Di Campli E, Di Bartolomeo S, Cataldi V, Marzio L, Grossi L, Ciccaglione AF, Nostro A, Cellini L. In vitro antimicrobial susceptibility of Helicobacter pylori to nine antibiotics currently used in Central Italy. Scand J Gastroenterol. 2016;51:263-269. [PMID: 26554617 DOI: 10.3109/00365521.2015.1092577] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
178 Moennighoff C, Thomas N, Nienhaus F, Hartmann M, Menrath A, Merkel J, Detlefsen H, Kreienbrock L, Hennig-Pauka I. Phenotypic antimicrobial resistance in Escherichia coli strains isolated from swine husbandries in North Western Germany - temporal patterns in samples from laboratory practice from 2006 to 2017. BMC Vet Res 2020;16:37. [PMID: 32013971 DOI: 10.1186/s12917-020-2268-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
179 Liou JM, Bair MJ, Chen CC, Lee YC, Chen MJ, Chen CC, Tseng CH, Fang YJ, Lee JY, Yang TH, Luo JC, Wu JY, Chang WH, Chang CC, Chen CY, Chen PY, Shun CT, Hsu WF, Hung HW, Lin JT, Chang CY, Wu MS; Taiwan Gastrointestinal Disease and Helicobacter Consortium. Levofloxacin Sequential Therapy vs Levofloxacin Triple Therapy in the Second-Line Treatment of Helicobacter pylori: A Randomized Trial. Am J Gastroenterol. 2016;111:381-387. [PMID: 26832653 DOI: 10.1038/ajg.2015.439] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 6.6] [Reference Citation Analysis]
180 Sriskandarajah P, Dearden CE. Epidemiology and environmental aspects of marginal zone lymphomas. Best Pract Res Clin Haematol 2017;30:84-91. [PMID: 28288721 DOI: 10.1016/j.beha.2016.07.002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
181 Wang B, Lv ZF, Wang YH, Wang H, Liu XQ, Xie Y, Zhou XJ. Standard triple therapy for Helicobacter pylori infection in China: a meta-analysis. World J Gastroenterol. 2014;20:14973-14985. [PMID: 25356059 DOI: 10.3748/wjg.v20.i40.14973] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
182 Mitui M, Patel A, Leos NK, Doern CD, Park JY. Novel Helicobacter pylori sequencing test identifies high rate of clarithromycin resistance. J Pediatr Gastroenterol Nutr. 2014;59:6-9. [PMID: 25222804 DOI: 10.1097/mpg.0000000000000380] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.4] [Reference Citation Analysis]
183 Jung YS, Kim EH, Park CH. Systematic review with meta-analysis: The efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication. Aliment Pharmacol Ther. 2017;46:106-114. [PMID: 28497487 DOI: 10.1111/apt.14130] [Cited by in Crossref: 59] [Cited by in F6Publishing: 47] [Article Influence: 14.8] [Reference Citation Analysis]
184 Lee JY, Park KS. Optimal First-Line Treatment for Helicobacter pylori Infection: Recent Strategies. Gastroenterol Res Pract 2016;2016:9086581. [PMID: 28070184 DOI: 10.1155/2016/9086581] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
185 Bluemel B, Goelz H, Goldmann B, Grüger J, Hamel H, Loley K, Ludolph T, Meyer J, Miehlke S, Mohr A, Tüffers K, Usadel H, Wagner S, Wenzel H, Wiemer L, Vorreiter J, Eisele B, Hofreuter D, Glocker EO. Antimicrobial resistance of Helicobacter pylori in Germany, 2015 to 2018. Clin Microbiol Infect 2020;26:235-9. [PMID: 31212078 DOI: 10.1016/j.cmi.2019.06.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
186 Bouihat N, Burucoa C, Benkirane A, Seddik H, Sentissi S, Al Bouzidi A, Elouennas M, Benouda A. Helicobacter pylori Primary Antibiotic Resistance in 2015 in Morocco: A Phenotypic and Genotypic Prospective and Multicenter Study. Microb Drug Resist. 2017;23:727-732. [PMID: 27996373 DOI: 10.1089/mdr.2016.0264] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.6] [Reference Citation Analysis]
187 Wüppenhorst N, Draeger S, Stüger HP, Hobmaier B, Vorreiter J, Kist M, Glocker EO; ResiNet Study Group. Prospective multicentre study on antimicrobial resistance of Helicobacter pylori in Germany. J Antimicrob Chemother. 2014;69:3127-3133. [PMID: 24997315 DOI: 10.1093/jac/dku243] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
188 Mégraud F, Bessède E, Varon C. Helicobacter pylori infection and gastric carcinoma. Clinical Microbiology and Infection 2015;21:984-90. [DOI: 10.1016/j.cmi.2015.06.004] [Cited by in Crossref: 35] [Cited by in F6Publishing: 27] [Article Influence: 5.8] [Reference Citation Analysis]
189 Megraud F, Gisbert JP. Towards effective empirical treatment for Helicobacter pylori eradication. Lancet 2016;388:2325-6. [PMID: 27769561 DOI: 10.1016/S0140-6736(16)31657-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
190 Wueppenhorst N, Stueger HP, Kist M, Glocker EO. High secondary resistance to quinolones in German Helicobacter pylori clinical isolates. J Antimicrob Chemother. 2013;68:1562-1566. [PMID: 23463210 DOI: 10.1093/jac/dkt061] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 4.4] [Reference Citation Analysis]
191 Miftahussurur M, Waskito LA, Syam AF, Nusi IA, Siregar G, Richardo M, Bakry AF, Rezkitha YAA, Wibawa IDN, Yamaoka Y. Alternative eradication regimens for Helicobacter pylori infection in Indonesian regions with high metronidazole and levofloxacin resistance. Infect Drug Resist. 2019;12:345-358. [PMID: 30774400 DOI: 10.2147/idr.s187063] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 6.5] [Reference Citation Analysis]
192 Gisbert JP, Calvet X. Helicobacter Pylori "Test-and-Treat" Strategy for Management of Dyspepsia: A Comprehensive Review. Clin Transl Gastroenterol 2013;4:e32. [PMID: 23535826 DOI: 10.1038/ctg.2013.3] [Cited by in Crossref: 34] [Cited by in F6Publishing: 22] [Article Influence: 4.3] [Reference Citation Analysis]
193 Georgopoulos SD, Papastergiou V, Karatapanis S. Treatment of Helicobacter Pylori infection: optimization strategies in a high resistance era. Expert Opin Pharmacother. 2015;16:2307-2317. [PMID: 26330278 DOI: 10.1517/14656566.2015.1084503] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
194 Ailloud F, Didelot X, Woltemate S, Pfaffinger G, Overmann J, Bader RC, Schulz C, Malfertheiner P, Suerbaum S. Within-host evolution of Helicobacter pylori shaped by niche-specific adaptation, intragastric migrations and selective sweeps. Nat Commun. 2019;10:2273. [PMID: 31118420 DOI: 10.1038/s41467-019-10050-1] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 16.5] [Reference Citation Analysis]
195 Song Z, Fu W, Zhou L. Cefuroxime, levofloxacin, esomeprazole, and bismuth as first-line therapy for eradicating Helicobacter pylori in patients allergic to penicillin. BMC Gastroenterol 2019;19:132. [PMID: 31345165 DOI: 10.1186/s12876-019-1056-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
196 Nyssen OP, Pérez-Aisa Á, Tepes B, Rodrigo-Sáez L, Romero PM, Lucendo A, Castro-Fernández M, Phull P, Barrio J, Bujanda L, Ortuño J, Areia M, Brglez Jurecic N, Huguet JM, Alcaide N, Voynovan I, María Botargues Bote J, Modolell I, Pérez Lasala J, Ariño I, Jonaitis L, Dominguez-Cajal M, Buzas G, Lerang F, Perona M, Bordin D, Axon T, Gasbarrini A, Marcos Pinto R, Niv Y, Kupcinskas L, Tonkic A, Leja M, Rokkas T, Boyanova L, Shvets O, Venerito M, Bytzer P, Goldis A, Simsek I, Lamy V, Przytulski K, Kunovský L, Capelle L, Milosavljevic T, Caldas M, Garre A, Mégraud F, O'Morain C, Gisbert JP; Hp-EuReg Investigators. Helicobacter pylori first-line and rescue treatments in patients allergic to penicillin: Experience from the European Registry on H pylori management (Hp-EuReg). Helicobacter 2020;25:e12686. [PMID: 32173974 DOI: 10.1111/hel.12686] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
197 Ferenc S, Gnus J, Kościelna M, Kinda M, Yarka A, Stewart L, Witkiewicz W. High antibiotic resistance of Helicobacter pylori and its effect on tailored and empiric eradication of the organism in Lower Silesia, Poland. Helicobacter 2017;22. [PMID: 27879042 DOI: 10.1111/hel.12365] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
198 Pellicano R, Fagoonee S. One or two weeks of treatment with Helicobacter Pylori ''standard'' triple therapy in the year 2015? Saudi J Gastroenterol 2015;21:343-4. [PMID: 26655127 DOI: 10.4103/1319-3767.170953] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
199 Kocazeybek B, Tokman HB. Prevalence of Primary Antimicrobial Resistance of H. pylori in Turkey: A Systematic Review. Helicobacter. 2016;21:251-260. [PMID: 26395982 DOI: 10.1111/hel.12272] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
200 Fischbach W, Malfertheiner P. Helicobacter Pylori Infection. Dtsch Arztebl Int. 2018;115:429-436. [PMID: 29999489 DOI: 10.3238/arztebl.2018.0429] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
201 Sung J, Kim N, Park YH, Hwang YJ, Kwon S, Na G, Choi JY, Kang JB, Kim HR, Kim J, Lee DH. Rifabutin-based Fourth and Fifth-line Rescue Therapy in Patients with for Helicobacter pylori Eradication Failure. Korean J Gastroenterol 2017;69:109. [DOI: 10.4166/kjg.2017.69.2.109] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
202 Gemilyan M, Hakobyan G, Benejat L, Allushi B, Melik-Nubaryan D, Mangoyan H, Laur A, Daguerre E, Grigoryan E, Megraud F. Prevalence of Helicobacter pylori infection and antibiotic resistance profile in Armenia. Gut Pathog 2019;11:28. [PMID: 31182977 DOI: 10.1186/s13099-019-0310-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
203 Chan CC, Chien NH, Lee CL, Yang YC, Hung CS, Tu TC, Wu CH. Comparison of 10-day sequential therapy with 7-day standard triple therapy for Helicobacter pylori eradication in inactive peptic ulcer disease and the efficiency of sequential therapy in inactive peptic ulcer disease and non-ulcer dyspepsia. BMC Gastroenterol 2015;15:170. [PMID: 26635102 DOI: 10.1186/s12876-015-0401-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
204 Dore MP, Bibbò S, Loria M, Salis R, Manca A, Pes GM, Graham DY. Twice-a-day PPI, tetracycline, metronidazole quadruple therapy with Pylera® or Lactobacillus reuteri for treatment naïve or for retreatment of Helicobacter pylori. Two randomized pilot studies. Helicobacter 2019;24:e12659. [PMID: 31502382 DOI: 10.1111/hel.12659] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
205 Tong YF, Lv J, Ying LY, Xu F, Qin B, Chen MT, Meng F, Tu MY, Yang NM, Li YM, Zhang JZ. Seven-day triple therapy is a better choice for Helicobacter pylori eradication in regions with low antibiotic resistance. World J Gastroenterol 2015;21:13073-9. [PMID: 26672777 DOI: 10.3748/wjg.v21.i46.13073] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
206 Graham DY, Dore MP, Lu H. Understanding treatment guidelines with bismuth and non-bismuth quadruple Helicobacter pylori eradication therapies. Expert Rev Anti Infect Ther. 2018;16:679-687. [PMID: 30102559 DOI: 10.1080/14787210.2018.1511427] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 8.3] [Reference Citation Analysis]
207 Morgan DR, Torres J, Sexton R, Herrero R, Salazar-Martínez E, Greenberg ER, Bravo LE, Dominguez RL, Ferreccio C, Lazcano-Ponce EC. Risk of recurrent Helicobacter pylori infection 1 year after initial eradication therapy in 7 Latin American communities. JAMA. 2013;309:578-586. [PMID: 23403682 DOI: 10.1001/jama. 2013.311] [Reference Citation Analysis]
208 Yang X, Wang JX, Han SX, Gao CP. High dose dual therapy versus bismuth quadruple therapy for Helicobacter pylori eradication treatment: A systematic review and meta-analysis. Medicine (Baltimore). 2019;98:e14396. [PMID: 30762742 DOI: 10.1097/md.0000000000014396] [Cited by in Crossref: 20] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]
209 Nijevitch AA, Idrisov B, Akhmadeeva EN, Graham DY. Choosing optimal first-line Helicobacter pylori therapy: a view from a region with high rates of antibiotic resistance. Curr Pharm Des 2014;20:4510-6. [PMID: 24180406 DOI: 10.2174/13816128113196660728] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
210 Georgopoulos SD, Papastergiou V, Karatapanis S. Current options for the treatment of Helicobacter pylori. Expert Opin Pharmacother. 2013;14:211-223. [PMID: 23331077 DOI: 10.1517/14656566.2013.763926] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 3.9] [Reference Citation Analysis]
211 Gunnarsdottir AI, Gudjonsson H, Hardardottir H, Jonsdottir KD, Bjornsson ES. Antibiotic susceptibility of Helicobacter pylori in Iceland. Infect Dis (Lond) 2017;49:647-54. [PMID: 28440099 DOI: 10.1080/23744235.2017.1317359] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
212 Yeo YH, Hsu CC, Lee CC, Ho HJ, Lin JT, Wu MS, Liou JM, Wu CY; Taiwan Gastrointestinal Disease and Helicobacter Consortium. Systematic review and network meta-analysis: Comparative effectiveness of therapies for second-line Helicobacter pylori eradication. J Gastroenterol Hepatol 2019;34:59-67. [PMID: 30169908 DOI: 10.1111/jgh.14462] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
213 Rhie SY, Park JY, Shin TS, Kim JW, Kim BJ, Kim JG. Discovery of a Novel Mutation in DNA Gyrase and Changes in the Fluoroquinolone Resistance of Helicobacter pylori over a 14-Year Period: A Single Center Study in Korea. Antibiotics (Basel) 2020;9:E287. [PMID: 32471292 DOI: 10.3390/antibiotics9060287] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
214 Senatore FJ, Wilmot J, Birk JW. Helicobacter pylori treatment: Still a work in progress. Postgrad Med. 2016;128:152-157. [PMID: 26490697 DOI: 10.1080/00325481.2016.1103194] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
215 Ierardi E, Giorgio F, Losurdo G, Di Leo A, Principi M. How antibiotic resistances could change Helicobacter pylori treatment: A matter of geography? World J Gastroenterol. 2013;19:8168-8180. [PMID: 24363506 DOI: 10.3748] [Reference Citation Analysis]
216 Apostolopoulos P, Ekmektzoglou K, Georgopoulos S, Chounta E, Theofanopoulou A, Kalantzis C, Vlachou E, Tsibouris P, Alexandrakis G. 10-Day Versus 14-Day Quadruple Concomitant Nonbismuth Therapy for the Treatment of Helicobacter pylori Infection: Results From a Randomized Prospective Study in a High Clarithromycin Resistance Country. J Clin Gastroenterol 2020;54:522-7. [PMID: 32028286 DOI: 10.1097/MCG.0000000000001328] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
217 McFarland LV, Huang Y, Wang L, Malfertheiner P. Systematic review and meta-analysis: Multi-strain probiotics as adjunct therapy for Helicobacter pylori eradication and prevention of adverse events. United European Gastroenterol J. 2016;4:546-561. [PMID: 27536365 DOI: 10.1177/2050640615617358] [Cited by in Crossref: 51] [Cited by in F6Publishing: 42] [Article Influence: 8.5] [Reference Citation Analysis]
218 Salar A. Gastric MALT lymphoma and Helicobacter pylori. Med Clin (Barc). 2019;152:65-71. [PMID: 30424932 DOI: 10.1016/j.medcli.2018.09.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
219 Ben Mansour K, Fendri C, Battikh H, Garnier M, Zribi M, Jlizi A, Burucoa C. Multiple and mixed Helicobacter pylori infections: Comparison of two epidemiological situations in Tunisia and France. Infection, Genetics and Evolution 2016;37:43-8. [DOI: 10.1016/j.meegid.2015.10.028] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
220 Costa S, Soares JB, Gonçalves R. Efficacy and tolerability of culture-guided treatment for Helicobacter pylori infection. Eur J Gastroenterol Hepatol 2017;29:1258-63. [PMID: 28877088 DOI: 10.1097/MEG.0000000000000960] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.7] [Reference Citation Analysis]
221 Arslan M, Balamtekin N, Günal A. Efficacy of a novel sequential treatment regimen containing bismuth for Helicobacter pylori eradication in Turkish children. Helicobacter 2020;25:e12757. [PMID: 32939900 DOI: 10.1111/hel.12757] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
222 Yang J, Song H, Cao K, Song J, Zhou J. Comprehensive analysis of Helicobacter pylori infection-associated diseases based on miRNA-mRNA interaction network. Brief Bioinform 2019;20:1492-501. [PMID: 29579224 DOI: 10.1093/bib/bby018] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 16.0] [Reference Citation Analysis]
223 Jaka H, Rhee JA, Östlundh L, Smart L, Peck R, Mueller A, Kasang C, Mshana SE. The magnitude of antibiotic resistance to Helicobacter pylori in Africa and identified mutations which confer resistance to antibiotics: systematic review and meta-analysis. BMC Infect Dis 2018;18:193. [PMID: 29699490 DOI: 10.1186/s12879-018-3099-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
224 Ciccaglione AF, Cellini L, Grossi L, Manzoli L, Marzio L. A Triple and Quadruple Therapy with Doxycycline and Bismuth for First-Line Treatment of Helicobacter pylori Infection: A Pilot Study. Helicobacter. 2015;20:390-396. [PMID: 25801708 DOI: 10.1111/hel.12209] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
225 McNicholl AG, Bordin DS, Lucendo A, Fadeenko G, Fernandez MC, Voynovan I, Zakharova NV, Sarsenbaeva AS, Bujanda L, Perez-Aisa Á, Vologzhanina L, Zaytsev O, Ilchishina T, Coba C, Lasala JP, Alekseenko S, Modolell I, Molina-Infante J, Ruiz-Zorrilla Lopez R, Alonso-Galan H, Moreno NF, Hinojosa J, Santaella I, Varela P, Gonzalez-Cordero PL, Barrio J, Dominguez-Jimenez JL, Nuñez O, Alcedo J, Nyssen OP, Caldas M, Donday MG, Shvetz O, Megraud F, O'Morain C, Gisbert JP. Combination of Bismuth and Standard Triple Therapy Eradicates Helicobacter pylori Infection in More than 90% of Patients. Clin Gastroenterol Hepatol 2020;18:89-98. [PMID: 30978536 DOI: 10.1016/j.cgh.2019.03.048] [Cited by in Crossref: 27] [Cited by in F6Publishing: 16] [Article Influence: 13.5] [Reference Citation Analysis]
226 Boltin D, Levi Z, Gingold-Belfer R, Gabay H, Shochat T, Schmilovitz-Weiss H, Dotan I, Birkenfeld S. Effect of Previous Nitroimidazole Treatment on Helicobacter pylori Eradication Success. J Clin Gastroenterol 2020;54:333-7. [PMID: 31305279 DOI: 10.1097/MCG.0000000000001237] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
227 Mouly C, Chati R, Scotté M, Regimbeau J. Therapeutic management of perforated gastro-duodenal ulcer: Literature review. Journal of Visceral Surgery 2013;150:333-40. [DOI: 10.1016/j.jviscsurg.2013.07.001] [Cited by in Crossref: 18] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
228 Gisbert JP, Molina-Infante J, Amador J, Bermejo F, Bujanda L, Calvet X, Castro-Fernández M, Cuadrado-Lavín A, Elizalde JI, Gene E, Gomollón F, Lanas Á, Martín de Argila C, Mearin F, Montoro M, Pérez-Aisa Á, Pérez-Trallero E, McNicholl AG. IV Spanish Consensus Conference on Helicobacter pylori infection treatment. Gastroenterol Hepatol 2016;39:697-721. [PMID: 27342080 DOI: 10.1016/j.gastrohep.2016.05.003] [Cited by in Crossref: 72] [Cited by in F6Publishing: 38] [Article Influence: 14.4] [Reference Citation Analysis]
229 Tepeš B, Vujasinović M, Šeruga M, Stefanovič M, Forte A, Jeverica S. Randomized clinical trial comparing 10-day sequential, 7-day concomitant and 7-day standard triple therapies for Helicobacter pylori eradication: . European Journal of Gastroenterology & Hepatology 2016;28:676-83. [DOI: 10.1097/meg.0000000000000590] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 2.6] [Reference Citation Analysis]
230 Branquinho D, Almeida N, Gregório C, Cabral JE, Casela A, Donato MM, Tomé L. Levofloxacin or Clarithromycin-based quadruple regimens: what is the best alternative as first-line treatment for Helicobacter pylori eradication in a country with high resistance rates for both antibiotics? BMC Gastroenterol 2017;17:31. [PMID: 28202013 DOI: 10.1186/s12876-017-0589-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
231 Gopal R, Elamurugan TP, Kate V, Jagdish S, Basu D. Standard triple versus levofloxacin based regimen for eradication of Helicobacter pylori. World J Gastrointest Pharmacol Ther. 2013;4:23-27. [PMID: 23667770 DOI: 10.4292/wjgpt.v4.i2.2] [Reference Citation Analysis]
232 Song Z, Zhou L, Zhang J, He L, Bai P, Xue Y. Levofloxacin, bismuth, amoxicillin and esomeprazole as second-line Helicobacter pylori therapy after failure of non-bismuth quadruple therapy. Dig Liver Dis. 2016;48:506-511. [PMID: 26847964 DOI: 10.1016/j.dld.2016.01.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
233 Silva GM, Silva HM, Nascimento J, Gonçalves J, Pereira F, Lima R. Helicobacter pylori antimicrobial resistance in a pediatric population. Helicobacter 2018;23:e12528. [DOI: 10.1111/hel.12528] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
234 Du S, Li Y, Su Z, Shi X, Johnson NL, Li P, Zhang Y, Zhang Q, Wen L, Li K, Chen Y, Zhang X, Fei Y, Ding X. Index-based dietary patterns in relation to gastric cancer risk: a systematic review and meta-analysis. Br J Nutr 2020;123:964-74. [PMID: 31767045 DOI: 10.1017/S0007114519002976] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
235 Molina-Infante J, Shiotani A. Practical Aspects in Choosing a Helicobacter pylori Therapy. Gastroenterol Clin North Am 2015;44:519-35. [PMID: 26314666 DOI: 10.1016/j.gtc.2015.05.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
236 Gisbert JP, McNicholl AG. Optimization strategies aimed to increase the efficacy of H. pylori eradication therapies. Helicobacter. 2017;22. [PMID: 28464347 DOI: 10.1111/hel.12392] [Cited by in Crossref: 37] [Cited by in F6Publishing: 25] [Article Influence: 9.3] [Reference Citation Analysis]
237 Boltin D, Levi Z, Gingold-Belfer R, Gabay H, Shochat T, Niv Y, Dickman R, Dotan I, Birkenfeld S. Impact of Previous Exposure to Macrolide Antibiotics on Helicobacter pylori Infection Treatment Outcomes. Am J Gastroenterol 2019;114:900-6. [PMID: 31095531 DOI: 10.14309/ajg.0000000000000223] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 10.0] [Reference Citation Analysis]
238 Liou J, Chen P, Luo J, Lee J, Chen C, Fang Y, Yang T, Chang C, Bair M, Chen M, Hsu Y, Hsu W, Chang C, Lin J, Shun C, El-omar EM, Wu M, Liou J, Lee Y, Lin J, Wu C, Wu J, Chen C, Lin C, Fang Y, Bair M, Luo J, Wu M, Cheng T, Tseng P, Chiu H, Chang C, Yu C, Chiu M, Chen Y, Hu W, Chou C, Tai C, Lee C, Wang W, Chang W. Efficacies of Genotypic Resistance-Guided vs Empirical Therapy for Refractory Helicobacter pylori Infection. Gastroenterology 2018;155:1109-19. [DOI: 10.1053/j.gastro.2018.06.047] [Cited by in Crossref: 33] [Cited by in F6Publishing: 21] [Article Influence: 11.0] [Reference Citation Analysis]
239 Perrone S, D'Elia GM, Annechini G, Pulsoni A. Infectious Aetiology of Marginal Zone Lymphoma and Role of Anti-Infective Therapy. Mediterr J Hematol Infect Dis 2016;8:e2016006. [PMID: 26740867 DOI: 10.4084/MJHID.2016.006] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
240 Krzyżek P, Franiczek R, Krzyżanowska B, Łaczmański Ł, Migdał P, Gościniak G. In Vitro Activity of 3-Bromopyruvate, an Anticancer Compound, Against Antibiotic-Susceptible and Antibiotic-Resistant Helicobacter pylori Strains. Cancers (Basel) 2019;11:E229. [PMID: 30781380 DOI: 10.3390/cancers11020229] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
241 Skouloubris S, Djaout K, Lamarre I, Lambry JC, Anger K, Briffotaux J, Liebl U, de Reuse H, Myllykallio H. Targeting of Helicobacter pylori thymidylate synthase ThyX by non-mitotoxic hydroxy-naphthoquinones. Open Biol 2015;5:150015. [PMID: 26040760 DOI: 10.1098/rsob.150015] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
242 Talebi Bezmin Abadi A. Novel Idea: Virulence-Based Therapy Against Helicobacter pylori Infection (Smart Therapy). Front Med (Lausanne). 2014;1:18. [PMID: 25705629 DOI: 10.3389/fmed.2014.00018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
243 Song ZQ, Zhou LY. Hybrid, sequential and concomitant therapies for Helicobacter pylori eradication: A systematic review and meta-analysis. World J Gastroenterol. 2016;22:4766-4775. [PMID: 27217708 DOI: 10.3748/wjg.v22.i19.4766] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
244 Phan TN, Santona A, Tran VH, Tran TN, Le VA, Cappuccinelli P, Rubino S, Paglietti B. High rate of levofloxacin resistance in a background of clarithromycin- and metronidazole-resistant Helicobacter pylori in Vietnam. Int J Antimicrob Agents. 2015;45:244-248. [PMID: 25499186 DOI: 10.1016/j.ijantimicag.2014.10.019] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 4.7] [Reference Citation Analysis]
245 Kutluk G, Tutar E, Bayrak A, Volkan B, Akyon Y, Celikel C, Ertem D. Sequential therapy versus standard triple therapy for Helicobacter pylori eradication in children: any advantage in clarithromycin-resistant strains? Eur J Gastroenterol Hepatol. 2014;26:1202-1208. [PMID: 25171023 DOI: 10.1097/meg.0000000000000190] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
246 Smith SM. Role of Toll-like receptors in Helicobacter pylori infection and immunity. World J Gastrointest Pathophysiol. 2014;5:133-146. [PMID: 25133016 DOI: 10.4291/wjgp.v5.i3.133] [Cited by in CrossRef: 50] [Cited by in F6Publishing: 43] [Article Influence: 7.1] [Reference Citation Analysis]
247 Lee JY, Kim N, Nam RH, In Choi S, Lee JW, Lee DH. Primary and secondary antibiotic resistance of Helicobacter pylori in Korea from 2003 to 2018. Helicobacter. 2019;24:e12660. [PMID: 31507036 DOI: 10.1111/hel.12660] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 8.5] [Reference Citation Analysis]
248 Wang ZJ, Chen XF, Zhang ZX, Li YC, Deng J, Tu J, Song ZQ, Zou QH. Effects of anti-Helicobacter pylori concomitant therapy and probiotic supplementation on the throat and gut microbiota in humans. Microb Pathog 2017;109:156-61. [PMID: 28552806 DOI: 10.1016/j.micpath.2017.05.035] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
249 Molina-Infante J, Lucendo AJ, Angueira T, Rodriguez-Tellez M, Perez-Aisa A, Balboa A, Barrio J, Martin-Noguerol E, Gomez-Rodriguez BJ, Botargues-Bote JM, Gomez-Camarero J, Huerta A, Modolell I, Ariño I, Herranz-Bachiller MT, Bermejo F, McNicholl AG, O'Morain C, Gisbert JP; European Registry on H. pylori management (Hp‐EuReg). Optimised empiric triple and concomitant therapy for Helicobacter pylori eradication in clinical practice: the OPTRICON study. Aliment Pharmacol Ther 2015;41:581-9. [PMID: 25776067 DOI: 10.1111/apt.13069] [Cited by in Crossref: 53] [Cited by in F6Publishing: 37] [Article Influence: 8.8] [Reference Citation Analysis]
250 Papastergiou V, Georgopoulos SD, Karatapanis S. Treatment of Helicobacter pylori infection: meeting the challenge of antimicrobial resistance. World J Gastroenterol 2014;20:9898-911. [PMID: 25110420 DOI: 10.3748/wjg.v20.i29.9898] [Cited by in CrossRef: 55] [Cited by in F6Publishing: 46] [Article Influence: 9.2] [Reference Citation Analysis]
251 Tepes B, Kastelic M, Vujasinovic M, Lampic P, Seruga M, Jurecic NB, Nyssen OP, Donday MG, O'Morain C, Megraud F, McNicholl AG, Gisbert JP. Helicobacter Pylori Treatment Results in Slovenia in the Period 2013-2015 as a Part of European Registry on Helicobacter Pylori Management. Radiol Oncol 2018;52:1-6. [PMID: 29520199 DOI: 10.1515/raon-2017-0055] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
252 Song ZQ, Liu J, Zhou LY. Hybrid Therapy Regimen for Helicobacter Pylori Eradication. Chin Med J (Engl). 2016;129:992-999. [PMID: 27064046 DOI: 10.4103/0366-6999.179803] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
253 Martos M, Bujanda L, Salicio Y, Sarasqueta C, Ibarra B, Mendarte U, Fernández-Reyes M, Cosme A. Clarithromycin for first-line treatment of Helicobacter pylori infection after culture in high-resistance regions. Eur J Gastroenterol Hepatol. 2014;26:1380-1384. [PMID: 25229983 DOI: 10.1097/meg.0000000000000197] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
254 McNicholl AG, Marin AC, Molina-Infante J, Castro M, Barrio J, Ducons J, Calvet X, de la Coba C, Montoro M, Bory F. Randomised clinical trial comparing sequential and concomitant therapies for Helicobacter pylori eradication in routine clinical practice. Gut. 2014;63:244-249. [PMID: 23665990 DOI: 10.1136/gutjnl-2013-304820] [Cited by in Crossref: 83] [Cited by in F6Publishing: 75] [Article Influence: 10.4] [Reference Citation Analysis]
255 Kahramanoğlu Aksoy E, Pirinçci Sapmaz F, Göktaş Z, Uzman M, Nazlıgül Y. Comparison of Helicobacter pylori Eradication Rates of 2-Week Levofloxacin-Containing Triple Therapy, Levofloxacin-Containing Bismuth Quadruple Therapy, and Standard Bismuth Quadruple Therapy as a First-Line Regimen. Med Princ Pract 2017;26:523-9. [PMID: 29131124 DOI: 10.1159/000484930] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
256 Kim SY, Chung JW. Best Helicobacter pylori Eradication Strategy in the Era of Antibiotic Resistance. Antibiotics (Basel) 2020;9:E436. [PMID: 32717826 DOI: 10.3390/antibiotics9080436] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
257 Voidarou CC, Rozos G, Alexopoulos A, Plessas S, Mantzourani I, Stavropoulou E, Tzora A, Bezirtzoglou E. In Vitro Screening Potential Antibacterial Properties of the Greek Oregano Honey against Clinical Isolates of Helicobacter pylori. Foods 2021;10:1568. [PMID: 34359441 DOI: 10.3390/foods10071568] [Reference Citation Analysis]
258 Baylina M, Muñoz N, Sánchez-Delgado J, López-Góngora S, Calvet X, Puig I. Systematic review: Would susceptibility-guided treatment achieve acceptable cure rates for second-line Helicobacter pylori therapy as currently practiced? Helicobacter 2019;24:e12584. [PMID: 30990575 DOI: 10.1111/hel.12584] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
259 Jehanne Q, Bénéjat L, Mégraud F, Bessède E, Lehours P. Evaluation of the Allplex™ H pylori and ClariR PCR Assay for Helicobacter pylori detection on gastric biopsies. Helicobacter 2020;25:e12702. [PMID: 32426894 DOI: 10.1111/hel.12702] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
260 Miftahussurur M, Shrestha PK, Subsomwong P, Sharma RP, Yamaoka Y. Emerging Helicobacter pylori levofloxacin resistance and novel genetic mutation in Nepal. BMC Microbiol. 2016;16:256. [PMID: 27809767 DOI: 10.1186/s12866-016-0873-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
261 Mégraud F. The challenge of Helicobacter pylori resistance to antibiotics: the comeback of bismuth-based quadruple therapy. Therap Adv Gastroenterol. 2012;5:103-109. [PMID: 22423259 DOI: 10.1177/1756283x11432492] [Cited by in Crossref: 78] [Cited by in F6Publishing: 22] [Article Influence: 8.7] [Reference Citation Analysis]
262 Ergül B, Koçak E, Taş A, Filik L, Köklü S. Bismuth, moxifloxacin, tetracycline, lansoprazole quadruple first line therapy for eradication of H. pylori: A prospective study. Clin Res Hepatol Gastroenterol 2013;37:527-9. [PMID: 23312494 DOI: 10.1016/j.clinre.2012.10.014] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
263 Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol. 2017;112:212-239. [PMID: 28071659 DOI: 10.1038/ajg.2016.563] [Cited by in Crossref: 515] [Cited by in F6Publishing: 343] [Article Influence: 128.8] [Reference Citation Analysis]
264 Gisbert JP, Calvet X, Bermejo F, Boixeda D, Bory F, Bujanda L, Castro-Fernández M, Dominguez-Muñoz E, Elizalde JI, Forné M, Gené E, Gomollón F, Lanas Á, Martín de Argila C, McNicholl AG, Mearin F, Molina-Infante J, Montoro M, Pajares JM, Pérez-Aisa A, Pérez-Trallero E, Sánchez-Delgado J. [III Spanish Consensus Conference on Helicobacter pylori infection]. Gastroenterol Hepatol 2013;36:340-74. [PMID: 23601856 DOI: 10.1016/j.gastrohep.2013.01.011] [Cited by in Crossref: 49] [Cited by in F6Publishing: 21] [Article Influence: 6.1] [Reference Citation Analysis]
265 Cerqueira RM, Correia M, Vilar H, Manso MC. Cumulative Helicobacter Pylori Eradication Rates by Adopting First- and Second- Line Regimens Proposed by the Maastricht IV Consensus in Obese Patients Undergoing Gastric Bypass Surgery. Obes Surg 2018;28:743-7. [PMID: 29076008 DOI: 10.1007/s11695-017-2915-z] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
266 Dargiene G, Kupcinskas J, Jonaitis L, Vezbavicius M, Kadusevicius E, Kupcinskiene E, Frandsen TH, Kucinskiene R, Kupcinskas L, Andersen LP. Primary antibiotic resistance of Helicobacter pylori strains among adults and children in a tertiary referral centre in Lithuania. APMIS 2018;126:21-8. [DOI: 10.1111/apm.12752] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
267 Kachalov VN, Nguyen H, Balakrishna S, Salazar-Vizcaya L, Sommerstein R, Kuster SP, Hauser A, Abel Zur Wiesch P, Klein E, Kouyos RD. Identifying the drivers of multidrug-resistant Klebsiella pneumoniae at a European level. PLoS Comput Biol 2021;17:e1008446. [PMID: 33513129 DOI: 10.1371/journal.pcbi.1008446] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
268 Boyanova L, Gergova G, Evstatiev I, Spassova Z, Kandilarov N, Yaneva P, Markovska R, Mitov I. Helicobacter pylori resistance to six antibiotics by two breakpoint systems and resistance evolution in Bulgaria. Infectious Diseases 2015;48:56-62. [DOI: 10.3109/23744235.2015.1082035] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
269 Boltin D, Ben-Zvi H, Perets TT, Kamenetsky Z, Samra Z, Dickman R, Niv Y. Trends in secondary antibiotic resistance of Helicobacter pylori from 2007 to 2014: has the tide turned? J Clin Microbiol. 2015;53:522-527. [PMID: 25428158 DOI: 10.1128/jcm.03001-14] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 2.4] [Reference Citation Analysis]
270 Mascellino MT, Porowska B, De Angelis M, Oliva A. Antibiotic susceptibility, heteroresistance, and updated treatment strategies in Helicobacter pylori infection. Drug Des Devel Ther 2017;11:2209-20. [PMID: 28814829 DOI: 10.2147/DDDT.S136240] [Cited by in Crossref: 19] [Cited by in F6Publishing: 5] [Article Influence: 4.8] [Reference Citation Analysis]
271 Van den Poel B, Gils S, Micalessi I, Carton S, Christiaens P, Cuyle PJ, Moons V, Van Olmen G, Smismans A, Bourgain C, Bossuyt P, Frans J. Molecular detection of Helicobacter pylori and clarithromycin resistance in gastric biopsies: a prospective evaluation of RIDA®GENE Helicobacter pylori assay. Acta Clin Belg 2021;76:177-83. [PMID: 31662122 DOI: 10.1080/17843286.2019.1685741] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
272 Malfertheiner P, Megraud F, O'Morain CA, Gisbert JP, Kuipers EJ, Axon AT, Bazzoli F, Gasbarrini A, Atherton J, Graham DY, Hunt R, Moayyedi P, Rokkas T, Rugge M, Selgrad M, Suerbaum S, Sugano K, El-Omar EM; European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017;66:6-30. [PMID: 27707777 DOI: 10.1136/gutjnl-2016-312288] [Cited by in Crossref: 1166] [Cited by in F6Publishing: 805] [Article Influence: 233.2] [Reference Citation Analysis]
273 Saracino IM, Pavoni M, Zullo A, Fiorini G, Saccomanno L, Lazzarotto T, Cavallo R, Antonelli G, Vaira D. Antibiotic Resistance and Therapy Outcome in H. pylori Eradication Failure Patients. Antibiotics (Basel) 2020;9:E121. [PMID: 32183165 DOI: 10.3390/antibiotics9030121] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
274 Zagari RM, Romano M, Ojetti V, Stockbrugger R, Gullini S, Annibale B, Farinati F, Ierardi E, Maconi G, Rugge M, Calabrese C, Di Mario F, Luzza F, Pretolani S, Savio A, Gasbarrini G, Caselli M. Guidelines for the management of Helicobacter pylori infection in Italy: The III Working Group Consensus Report 2015. Dig Liver Dis. 2015;47:903-912. [PMID: 26253555 DOI: 10.1016/j.dld.2015.06.010] [Cited by in Crossref: 70] [Cited by in F6Publishing: 65] [Article Influence: 11.7] [Reference Citation Analysis]
275 Hussein NR, Tunjel I, Majed HS, Yousif ST, Aswad SI, Assafi MS. Duodenal ulcer promoting gene 1 (dupA1) is associated with A2147G clarithromycin-resistance mutation but not interleukin-8 secretion from gastric mucosa in Iraqi patients. New Microbes New Infect. 2015;6:5-10. [PMID: 26042186 DOI: 10.1016/j.nmni.2015.02.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
276 Cosme A, Lizasoan J, Montes M, Tamayo E, Alonso H, Mendarte U, Martos M, Fernández-Reyes M, Saraqueta C, Bujanda L. Antimicrobial Susceptibility-Guided Therapy Versus Empirical Concomitant Therapy for Eradication of Helicobacter pylori in a Region with High Rate of Clarithromycin Resistance. Helicobacter 2016;21:29-34. [PMID: 25982426 DOI: 10.1111/hel.12231] [Cited by in Crossref: 34] [Cited by in F6Publishing: 25] [Article Influence: 5.7] [Reference Citation Analysis]
277 Li Y, Chen Z, Ye J, Ning L, Luo J, Zhang L, Jiang Y, Xi Y, Ning Y. Antibody Production and Th1-biased Response Induced by an Epitope Vaccine Composed of Cholera Toxin B Unit and Helicobacter pylori Lpp20 Epitopes. Helicobacter 2016;21:234-48. [PMID: 26332255 DOI: 10.1111/hel.12268] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
278 Smith SM, O'Morain C, McNamara D. Antimicrobial susceptibility testing for Helicobacter pylori in times of increasing antibiotic resistance. World J Gastroenterol. 2014;20:9912-9921. [PMID: 25110421 DOI: 10.3748/wjg.v20.i29.9912] [Cited by in CrossRef: 69] [Cited by in F6Publishing: 64] [Article Influence: 11.5] [Reference Citation Analysis]
279 Nyssen OP, Bordin D, Tepes B, Pérez-Aisa Á, Vaira D, Caldas M, Bujanda L, Castro-Fernandez M, Lerang F, Leja M, Rodrigo L, Rokkas T, Kupcinskas L, Pérez-Lasala J, Jonaitis L, Shvets O, Gasbarrini A, Simsek H, Axon ATR, Buzás G, Machado JC, Niv Y, Boyanova L, Goldis A, Lamy V, Tonkic A, Przytulski K, Beglinger C, Venerito M, Bytzer P, Capelle L, Milosavljević T, Milivojevic V, Veijola L, Molina-Infante J, Vologzhanina L, Fadeenko G, Ariño I, Fiorini G, Garre A, Garrido J, F Pérez C, Puig I, Heluwaert F, Megraud F, O'Morain C, Gisbert JP; Hp-EuReg Investigators. European Registry on Helicobacter pylori management (Hp-EuReg): patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21 533 patients. Gut 2021;70:40-54. [PMID: 32958544 DOI: 10.1136/gutjnl-2020-321372] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 20.0] [Reference Citation Analysis]
280 Tariq H, Patel H, Kamal MU, Abbas N, Ameen M, Azam S, Kumar K, Ravi M, Vootla V, Shaikh D, Amanchi V, Hussain AN, Makker J. Reevaluation of the Efficacy of First Line Regimen for Helicobacter pylori. Clin Exp Gastroenterol 2020;13:25-33. [PMID: 32158248 DOI: 10.2147/CEG.S239343] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
281 Kenyon C. Population-level macrolide consumption is associated with clarithromycin resistance in Helicobacter pylori: An ecological analysis. Int J Infect Dis 2019;85:67-9. [PMID: 31150843 DOI: 10.1016/j.ijid.2019.05.028] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
282 Quek C, Pham ST, Tran KT, Pham BT, Huynh LV, Luu NB, Le TK, Quek K, Pham VH. Antimicrobial susceptibility and clarithromycin resistance patterns of Helicobacter pylori clinical isolates in Vietnam. F1000Res 2016;5:671. [PMID: 27583131 DOI: 10.12688/f1000research.8239.1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 3.2] [Reference Citation Analysis]
283 Lin TJ, Lee HC, Lin CL, Wang CK, Chen KY, Wu DC. CYP2C19 polymorphism has no influence on rabeprazole-based hybrid therapy for Helicobacter pylori eradication. World J Clin Cases 2018;6:514-20. [PMID: 30397607 DOI: 10.12998/wjcc.v6.i12.514] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
284 Walker MM, Talley NJ. Review article: bacteria and pathogenesis of disease in the upper gastrointestinal tract--beyond the era of Helicobacter pylori. Aliment Pharmacol Ther. 2014;39:767-779. [PMID: 24612362 DOI: 10.1111/apt.12666] [Cited by in Crossref: 65] [Cited by in F6Publishing: 51] [Article Influence: 9.3] [Reference Citation Analysis]
285 Tadjrobehkar O, Abdollahi H. A Novel Reduction Strategy of Clarithromycin Resistance in Helicobacter pylori. Jundishapur J Microbiol. 2014;7:e13081. [PMID: 25741431 DOI: 10.5812/jjm.13081] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
286 Draeger S, Wüppenhorst N, Kist M, Glocker EO. Outcome of second- and third-line Helicobacter pylori eradication therapies based on antimicrobial susceptibility testing. J Antimicrob Chemother 2015;70:3141-5. [PMID: 26245638 DOI: 10.1093/jac/dkv223] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
287 Hays C, Burucoa C, Lehours P, Tran CT, Leleu A, Raymond J. Molecular characterization of Helicobacter pylori resistance to rifamycins. Helicobacter 2018;23. [PMID: 29168600 DOI: 10.1111/hel.12451] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
288 Schwarzer A, Bontems P, Urruzuno P, Kalach N, Iwanczak B, Roma-giannikou E, Sykora J, Kindermann A, Casswall T, Cadranel S, Koletzko S. Sequential Therapy for Helicobacter pylori Infection in Treatment-naïve Children. Helicobacter 2016;21:106-13. [DOI: 10.1111/hel.12240] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
289 Seddik H, Ahid S, El Adioui T, El Hamdi FZ, Hassar M, Abouqal R, Cherrah Y, Benkirane A. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: A prospective randomized study. Eur J Clin Pharmacol. 2013;69:1709-1715. [PMID: 23695545 DOI: 10.1007/s00228-013-1524-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
290 Albasha AM, Elnosh MM, Osman EH, Zeinalabdin DM, Fadl AAM, Ali MA, Altayb HN. Helicobacter pylori 23S rRNA gene A2142G, A2143G, T2182C, and C2195T mutations associated with clarithromycin resistance detected in Sudanese patients. BMC Microbiol 2021;21:38. [PMID: 33535966 DOI: 10.1186/s12866-021-02096-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
291 Andreev DN, Maev IV, Kucheryavyi YA, Dicheva DT, Partsvania-Vinogradova EV. [The efficiency and safety of anti-Helicobacter pylori therapy in patients with concomitant chronic hepatitis C]. Ter Arkh 2016;88:75-81. [PMID: 27070167 DOI: 10.17116/terarkh201688475-81] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 2.3] [Reference Citation Analysis]
292 An Y, Wang Y, Wu S, Wang YH, Qian X, Li Z, Fu YJ, Xie Y. Fourth-generation quinolones in the treatment of Helicobacter pylori infection: A meta-analysis. World J Gastroenterol 2018;24:3302-12. [PMID: 30090010 DOI: 10.3748/wjg.v24.i29.3302] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
293 Ghotaslou R, Leylabadlo HE, Asl YM. Prevalence of antibiotic resistance in Helicobacter pylori: A recent literature review. World J Methodol. 2015;5:164-174. [PMID: 26413490 DOI: 10.5662/wjm.v5.i3.164] [Cited by in CrossRef: 100] [Cited by in F6Publishing: 77] [Article Influence: 16.7] [Reference Citation Analysis]
294 Mahachai V, Vilaichone RK, Pittayanon R, Rojborwonwitaya J, Leelakusolvong S, Maneerattanaporn M, Chotivitayatarakorn P, Treeprasertsuk S, Kositchaiwat C, Pisespongsa P, Mairiang P, Rani A, Leow A, Mya SM, Lee YC, Vannarath S, Rasachak B, Chakravuth O, Aung MM, Ang TL, Sollano JD, Trong Quach D, Sansak I, Wiwattanachang O, Harnsomburana P, Syam AF, Yamaoka Y, Fock KM, Goh KL, Sugano K, Graham D. Helicobacter pylori management in ASEAN: The Bangkok consensus report. J Gastroenterol Hepatol. 2018;33:37-56. [PMID: 28762251 DOI: 10.1111/jgh.13911] [Cited by in Crossref: 51] [Cited by in F6Publishing: 42] [Article Influence: 17.0] [Reference Citation Analysis]
295 Muñoz-Gómez P, Jordán-Castro JA, Abanades-Tercero M, Blanco-González JJ, Andrés Esteban EM, Valle-Muñoz J. Macrolide use in the previous years is associated with failure to eradicate Helicobacter pylori with clarithromycin-containing regimens. Helicobacter 2018;23. [PMID: 29178562 DOI: 10.1111/hel.12452] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
296 Yang JC, Lin CJ, Wang HL, Chen JD, Kao JY, Shun CT, Lu CW, Lin BR, Shieh MJ, Chang MC, Chang YT, Wei SC, Lin LC, Yeh WC, Kuo JS, Tung CC, Leong YL, Wang TH, Wong JM. High-dose dual therapy is superior to standard first-line or rescue therapy for Helicobacter pylori infection. Clin Gastroenterol Hepatol. 2015;13:895-905.e5. [PMID: 25460556 DOI: 10.1016/j.cgh.2014.10.036] [Cited by in Crossref: 86] [Cited by in F6Publishing: 75] [Article Influence: 12.3] [Reference Citation Analysis]
297 Mégraud F. Antibiotic Resistance Is the Key Element in Treatment of Helicobacter pylori Infection. Gastroenterology 2018;155:1300-2. [DOI: 10.1053/j.gastro.2018.10.012] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
298 Ko SW, Kim YJ, Chung WC, Lee SJ. Bismuth supplements as the first-line regimen for Helicobacter pylori eradication therapy: Systemic review and meta-analysis. Helicobacter. 2019;24:e12565. [PMID: 30698318 DOI: 10.1111/hel.12565] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 12.0] [Reference Citation Analysis]
299 Valenzano M, Bisio A, Grassi G. Helicobacter pylori and diabetes mellitus: a controversial relationship. Minerva Endocrinol 2019;44:301-9. [PMID: 31304727 DOI: 10.23736/S0391-1977.19.03021-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
300 Raderer M, Kiesewetter B, Ferreri AJM. Clinicopathologic characteristics and treatment of marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma): Characteristics and Management of MALT Lymphoma. CA: A Cancer Journal for Clinicians 2016;66:152-71. [DOI: 10.3322/caac.21330] [Cited by in Crossref: 79] [Cited by in F6Publishing: 59] [Article Influence: 13.2] [Reference Citation Analysis]
301 Ahn HJ, Lee DS. Helicobacter pylori in gastric carcinogenesis. World J Gastrointest Oncol 2015;7:455-65. [PMID: 26690981 DOI: 10.4251/wjgo.v7.i12.455] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 27] [Article Influence: 5.0] [Reference Citation Analysis]
302 Vanden Bulcke A, Waked B, Haems L, Lambrecht G, Hervent AS, Alliet G, Baert F, Vervaeke S. Antimicrobial resistance of Helicobacter pylori in West Flanders - Belgium: an observational cross-sectional study. Acta Clin Belg 2021;:1-8. [PMID: 33502281 DOI: 10.1080/17843286.2021.1872307] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
303 Kori M, Le Thi TG, Werkstetter K, Sustmann A, Bontems P, Lopes AI, Oleastro M, Iwanczak B, Kalach N, Misak Z, Cabral J, Homan M, Cilleruelo Pascual ML, Pehlivanoglu E, Casswall T, Urruzuno P, Martinez Gomez MJ, Papadopoulou A, Roma E, Dolinsek J, Rogalidou M, Urbonas V, Chong S, Kindermann A, Miele E, Rea F, Cseh Á, Koletzko S; Helicobacter pylori Working Group of ESPGHAN. Helicobacter pylori Infection in Pediatric Patients Living in Europe: Results of the EuroPedHP Registry 2013 to 2016. J Pediatr Gastroenterol Nutr 2020;71:476-83. [PMID: 32541200 DOI: 10.1097/MPG.0000000000002816] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
304 Liang CM, Tai WC, Hsu PI, Wu DC, Kuo CH, Tsay FW, Lee CL, Chen KY, Chuah SK. Trend of changes in antibiotic resistance in Helicobacter pylori from 2013 to 2019: a multicentre report from Taiwan. Therap Adv Gastroenterol 2020;13:1756284820976990. [PMID: 33354229 DOI: 10.1177/1756284820976990] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
305 Blümel B, Goelz H, Kist M, Glocker E. Retrospective study on outcome of salvage Helicobacter pylori eradication therapies based on molecular genetic susceptibility testing. Helicobacter 2018;23:e12494. [DOI: 10.1111/hel.12494] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
306 Lyu T, Cheung KS, Ni L, Guo J, Mu P, Li Y, Yang Q, Yu X, Lyu Z, Wu J, Guo H, Leung WK, Seto WK. High prevalence and risk factors of multiple antibiotic resistance in patients who fail first-line Helicobacter pylori therapy in southern China: a municipality-wide, multicentre, prospective cohort study. J Antimicrob Chemother 2020;75:3391-4. [PMID: 32785699 DOI: 10.1093/jac/dkaa315] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
307 Sokic-Milutinovic A, Alempijevic T, Milosavljevic T. Role of Helicobacter pylori infection in gastric carcinogenesis: Current knowledge and future directions. World J Gastroenterol. 2015;21:11654-11672. [PMID: 26556993 DOI: 10.3748/wjg.v21.i41.11654] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
308 Burgos‐santamaría D, Mcnicholl AG, Gisbert JP. Empirical Helicobacter pylori rescue therapy: an 18‐year single‐centre study of 1200 patients. GastroHep 2019;1:311-24. [DOI: 10.1002/ygh2.372] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
309 Khien VV, Thang DM, Hai TM, Duat NQ, Khanh PH, Ha DT, Binh TT, Dung HDQ, Trang TTH, Yamaoka Y. Management of Antibiotic-Resistant Helicobacter pylori Infection: Perspectives from Vietnam. Gut Liver 2019;13:483-97. [PMID: 31009957 DOI: 10.5009/gnl18137] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
310 Gisbert JP, Perez-Aisa A, Rodrigo L, Molina-Infante J, Modolell I, Bermejo F, Castro-Fernández M, Antón R, Sacristán B, Cosme A. Third-line rescue therapy with bismuth-containing quadruple regimen after failure of two treatments (with clarithromycin and levofloxacin) for H. pylori infection. Dig Dis Sci. 2014;59:383-389. [PMID: 24126798 DOI: 10.1007/s10620-013-2900-x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 21] [Article Influence: 3.9] [Reference Citation Analysis]
311 Pohl D, Keller PM, Bordier V, Wagner K. Review of current diagnostic methods and advances in Helicobacter pylori diagnostics in the era of next generation sequencing. World J Gastroenterol 2019;25:4629-60. [PMID: 31528091 DOI: 10.3748/wjg.v25.i32.4629] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 18] [Article Influence: 26.0] [Reference Citation Analysis]
312 Regnath T, Raecke O, Enninger A, Ignatius R. Increasing metronidazole and rifampicin resistance of Helicobacter pylori isolates obtained from children and adolescents between 2002 and 2015 in southwest Germany. Helicobacter 2017;22. [PMID: 27400262 DOI: 10.1111/hel.12327] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
313 Mantegazza C, Molinari P, D’auria E, Sonnino M, Morelli L, Zuccotti GV. Probiotics and antibiotic-associated diarrhea in children: A review and new evidence on Lactobacillus rhamnosus GG during and after antibiotic treatment. Pharmacological Research 2018;128:63-72. [DOI: 10.1016/j.phrs.2017.08.001] [Cited by in Crossref: 53] [Cited by in F6Publishing: 41] [Article Influence: 17.7] [Reference Citation Analysis]
314 Nyssen OP, Perez-Aisa A, Castro-Fernandez M, Pellicano R, Huguet JM, Rodrigo L, Ortuñ J, O, Gomez-Rodriguez BJ, Pinto RM, Areia M, Perona M, Nuñez O, Romano M, Gravina AG, Pozzati L, Fernandez-Bermejo M, Venerito M, Malfertheiner P, Fernanadez-Salazar L, Gasbarrini A, Vaira D, Puig I, Megraud F, O'Morain C, Gisbert JP; Hp-EuReg investigators. European Registry on Helicobacter pylori management: Single-capsule bismuth quadruple therapy is effective in real-world clinical practice. United European Gastroenterol J 2021;9:38-46. [PMID: 33176617 DOI: 10.1177/2050640620972615] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
315 Baker L, Chitas AM, Hartley CA, Coppo MJ, Vaz PK, Stent A, Gilkerson JR, Devlin JM, Every AL. Recombinant herpesvirus glycoprotein G improves the protective immune response to Helicobacter pylori vaccination in a mouse model of disease. PLoS One 2014;9:e96563. [PMID: 24794215 DOI: 10.1371/journal.pone.0096563] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
316 Hathroubi S, Servetas SL, Windham I, Merrell DS, Ottemann KM. Helicobacter pylori Biofilm Formation and Its Potential Role in Pathogenesis. Microbiol Mol Biol Rev 2018;82:e00001-18. [PMID: 29743338 DOI: 10.1128/MMBR.00001-18] [Cited by in Crossref: 39] [Cited by in F6Publishing: 17] [Article Influence: 13.0] [Reference Citation Analysis]
317 Gatta L, Vakil N, Vaira D, Scarpignato C. Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy. BMJ. 2013;347:f4587. [PMID: 23926315 DOI: 10.1136/bmj.f4587] [Cited by in Crossref: 161] [Cited by in F6Publishing: 139] [Article Influence: 20.1] [Reference Citation Analysis]
318 O’Connor A, Molina-Infante J, Gisbert JP, O’Morain C. Treatment of Helicobacter pylori infection 2013. Helicobacter. 2013;18 Suppl 1:58-65. [PMID: 24011247 DOI: 10.1111/hel.12075] [Cited by in Crossref: 38] [Cited by in F6Publishing: 25] [Article Influence: 5.4] [Reference Citation Analysis]
319 Ribaldone DG, Fagoonee S, Astegiano M, Durazzo M, Morgando A, Sprujevnik T, Giordanino C, Baronio M, De Angelis C, Saracco GM, Pellicano R. Rifabutin-Based Rescue Therapy for Helicobacter pylori Eradication: A Long-Term Prospective Study in a Large Cohort of Difficult-to-Treat Patients. J Clin Med. 2019;8. [PMID: 30736338 DOI: 10.3390/jcm8020199] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 12.0] [Reference Citation Analysis]
320 Allahverdiyev AM, Bagirova M, Caliskan R, Tokman HB, Aliyeva H, Unal G, Oztel ON, Abamor ES, Toptas H, Yuksel P. Isolation and diagnosis of Helicobacter pylori by a new method: microcapillary culture. World J Gastroenterol. 2015;21:2622-2628. [PMID: 25759529 DOI: 10.3748/wjg.v21.i9.2622] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
321 Zollner-schwetz I, Leitner E, Plieschnegger W, Semlitsch G, Stepan V, Reiter L, Reicht G, Mörth E, Pavek J, Parsché P, Betterklieber C, Atzmüller D, Krause R, Högenauer C. Primary resistance of Helicobacter pylori is still low in Southern Austria. International Journal of Medical Microbiology 2016;306:206-11. [DOI: 10.1016/j.ijmm.2016.04.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
322 Chen MJ, Chen CC, Chen YN, Fang YJ, Lin JT, Wu MS, Liou JM;  Taiwan Gastrointestinal Disease Helicobacter Consortium. Systematic Review with Meta-Analysis: Concomitant Therapy vs. Triple Therapy for the First-Line Treatment of Helicobacter pylori Infection. Am J Gastroenterol. 2018;113:1444-1457. [PMID: 30171216 DOI: 10.1038/s41395-018-0217-2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 7.3] [Reference Citation Analysis]
323 Gopal R, Elamurugan TP, Kate V, Jagdish S, Basu D. Standard triple versus levofloxacin based regimen for eradication of Helicobacter pylori. World J Gastrointest Pharmacol Ther 2013;4:23-7. [PMID: 23667770 DOI: 10.4292/wjgpt.v4.i2.23] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
324 Aguilera-Correa JJ, Urruzuno P, Barrio J, Martinez MJ, Agudo S, Somodevilla A, Llorca L, Alarcón T. Detection of Helicobacter pylori and the genotypes of resistance to clarithromycin and the heterogeneous genotype to this antibiotic in biopsies obtained from symptomatic children. Diagn Microbiol Infect Dis 2017;87:150-3. [PMID: 27863951 DOI: 10.1016/j.diagmicrobio.2016.03.001] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 3.2] [Reference Citation Analysis]
325 Miftahussurur M, Syam AF, Nusi IA, Makmun D, Waskito LA, Zein LH, Akil F, Uwan WB, Simanjuntak D, Wibawa ID, Waleleng JB, Saudale AM, Yusuf F, Mustika S, Adi P, Maimunah U, Maulahela H, Rezkitha YA, Subsomwong P, Nasronudin, Rahardjo D, Suzuki R, Akada J, Yamaoka Y. Surveillance of Helicobacter pylori Antibiotic Susceptibility in Indonesia: Different Resistance Types among Regions and with Novel Genetic Mutations. PLoS One. 2016;11:e0166199. [PMID: 27906990 DOI: 10.1371/journal.pone.0166199] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 6.0] [Reference Citation Analysis]
326 Liu X, Wang H, Lv Z, Wang Y, Wang B, Xie Y, Zhou X, Lv N. Rescue Therapy with a Proton Pump Inhibitor Plus Amoxicillin and Rifabutin for Helicobacter pylori Infection: A Systematic Review and Meta-Analysis. Gastroenterol Res Pract 2015;2015:415648. [PMID: 26106411 DOI: 10.1155/2015/415648] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
327 Ji Y, Lu H. Meta-analysis: High-dose vs. low-dose metronidazole-containing therapies for Helicobacter pylori eradication treatment. PLoS One 2018;13:e0189888. [PMID: 29370199 DOI: 10.1371/journal.pone.0189888] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
328 Gopal R, Elamurugan TP, Kate V, Jagdish S, Basu D. Standard triple versus levofloxacin based regimen for eradication of Helicobacter pylori. World J Gastrointest Pharmacol Ther. 2013;4:23-27. [PMID: 23667770 DOI: 10.4292/wjgpt.v4.i2.23.PubMed] [Reference Citation Analysis]
329 Haider RB, Brennan DE, Omorogbe J, Holleran G, Hall B, O'Morain C, Breslin N, O'Connor HJ, Smith SM, McNamara D. A randomized-controlled study to compare the efficacy of sequential therapy with standard triple therapy for Helicobacter pylori eradication in an Irish population. Eur J Gastroenterol Hepatol. 2015;27:1265-1269. [PMID: 26287955 DOI: 10.1097/meg.0000000000000457] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
330 Ierardi E, Giorgio F, Iannone A, Losurdo G, Principi M, Barone M, Pisani A, Di Leo A. Noninvasive molecular analysis of Helicobacter pylori: Is it time for tailored first-line therapy? World J Gastroenterol. 2017;23:2453-2458. [PMID: 28465629 DOI: 10.3748/wjg.v23.i14.2453] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 20] [Article Influence: 6.7] [Reference Citation Analysis]
331 Xiao SP, Gu M, Zhang GX. Is levofloxacin-based triple therapy an alternative for first-line eradication of Helicobacter pylori A systematic review and meta-analysis. Scand J Gastroenterol. 2014;49:528-538. [PMID: 24611790 DOI: 10.3109/00365521.2014.887765] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
332 Ontsira Ngoyi EN, Atipo Ibara BI, Moyen R, Ahoui Apendi PC, Ibara JR, Obengui O, Ossibi Ibara RB, Nguimbi E, Niama RF, Ouamba JM, Yala F, Abena AA, Vadivelu J, Goh KL, Menard A, Benejat L, Sifre E, Lehours P, Megraud F. Molecular Detection of Helicobacter pylori and its Antimicrobial Resistance in Brazzaville, Congo. Helicobacter. 2015;20:316-320. [PMID: 25585658 DOI: 10.1111/hel.12204] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 4.7] [Reference Citation Analysis]
333 Loffeld RJ, Werdmuller BF. Changes in Antibiotic Susceptibility of Helicobacter pylori in the Course of Eight Years in the Zaanstreek Region in The Netherlands. Gastroenterol Res Pract 2013;2013:625937. [PMID: 23573077 DOI: 10.1155/2013/625937] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
334 Thung I, Aramin H, Vavinskaya V, Gupta S, Park JY, Crowe SE, Valasek MA. Review article: the global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther. 2016;43:514-533. [PMID: 26694080 DOI: 10.1111/apt.13497] [Cited by in Crossref: 310] [Cited by in F6Publishing: 241] [Article Influence: 51.7] [Reference Citation Analysis]
335 Soluri MF, Puccio S, Caredda G, Edomi P, D'Elios MM, Cianchi F, Troilo A, Santoro C, Sblattero D, Peano C. Defining the Helicobacter pylori Disease-Specific Antigenic Repertoire. Front Microbiol 2020;11:1551. [PMID: 32849324 DOI: 10.3389/fmicb.2020.01551] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
336 Song ZQ, Zhou LY. Helicobacter Pylori and Gastric Cancer: Clinical Aspects. Chin Med J (Engl) 2015;128:3101-5. [PMID: 26608993 DOI: 10.4103/0366-6999.169107] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
337 Jaka H, Rüttgerodt N, Bohne W, Mueller A, Gross U, Kasang C, Mshana SE. Helicobacter pylori Mutations Conferring Resistance to Fluoroquinolones and Clarithromycin among Dyspeptic Patients Attending a Tertiary Hospital, Tanzania. Can J Gastroenterol Hepatol 2019;2019:8481375. [PMID: 31355162 DOI: 10.1155/2019/8481375] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
338 Kwon YH, Jeon SW, Nam SY, Lee HS, Park JH. Efficacy of tailored therapy for Helicobacter pylori eradication based on clarithromycin resistance and survey of previous antibiotic exposure: A single-center prospective pilot study. Helicobacter. 2019;24:e12585. [PMID: 30969459 DOI: 10.1111/hel.12585] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
339 Redondo JJ, Keller PM, Zbinden R, Wagner K. A novel RT-PCR for the detection of Helicobacter pylori and identification of clarithromycin resistance mediated by mutations in the 23S rRNA gene. Diagn Microbiol Infect Dis. 2018;90:1-6. [PMID: 29111147 DOI: 10.1016/j.diagmicrobio.2017.09.014] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 5.5] [Reference Citation Analysis]
340 Jones NL, Koletzko S, Goodman K, Bontems P, Cadranel S, Casswall T, Czinn S, Gold BD, Guarner J, Elitsur Y, Homan M, Kalach N, Kori M, Madrazo A, Megraud F, Papadopoulou A, Rowland M, ESPGHAN, NASPGHAN. Joint ESPGHAN/NASPGHAN Guidelines for the Management of Helicobacter pylori in Children and Adolescents (Update 2016). J Pediatr Gastroenterol Nutr. 2017;64:991-1003. [PMID: 28541262 DOI: 10.1097/mpg.0000000000001594] [Cited by in Crossref: 134] [Cited by in F6Publishing: 29] [Article Influence: 33.5] [Reference Citation Analysis]
341 Malfertheiner P, Venerito M, Selgrad M. Helicobacter pylori infection: selected aspects in clinical management. Curr Opin Gastroenterol. 2013;29:669-675. [PMID: 24100726 DOI: 10.1097/mog.0b013e328365d443] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
342 Pérez-arellano E, Rodriguez-garcia MI, Galera Rodenas AB, de la Morena-madrigal E. Erradicación de la infección por Helicobacter pylori con una nueva terapia cuádruple basada en bismuto en la práctica clínica. Gastroenterología y Hepatología 2018;41:145-52. [DOI: 10.1016/j.gastrohep.2017.08.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
343 Im BN, Shin H, Lim B, Lee J, Kim KS, Park JM, Na K. Helicobacter pylori-targeting multiligand photosensitizer for effective antibacterial endoscopic photodynamic therapy. Biomaterials 2021;271:120745. [PMID: 33740616 DOI: 10.1016/j.biomaterials.2021.120745] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
344 Ierardi E, Giorgio F, Losurdo G, Di Leo A, Principi M. How antibiotic resistances could change Helicobacter pylori treatment: A matter of geography? World J Gastroenterol. 2013;19:8168-8180. [PMID: 24363506 DOI: 10.3748/wjg.v19.i45.8168] [Cited by in CrossRef: 62] [Cited by in F6Publishing: 59] [Article Influence: 8.9] [Reference Citation Analysis]
345 Fu W, Song Z, Zhou L, Xue Y, Ding Y, Suo B, Tian X, Wang L. Randomized Clinical Trial: Esomeprazole, Bismuth, Levofloxacin, and Amoxicillin or Cefuroxime as First-Line Eradication Regimens for Helicobacter pylori Infection. Dig Dis Sci 2017;62:1580-9. [DOI: 10.1007/s10620-017-4564-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
346 Malfertheiner P, Selgrad M. Helicobacter pylori. Curr Opin Gastroenterol. 2014;30:589-595. [PMID: 25268839 DOI: 10.1097/mog.0000000000000128] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
347 Ciccaglione AF, Di Giulio M, Di Lodovico S, Di Campli E, Cellini L, Marzio L. Bovine lactoferrin enhances the efficacy of levofloxacin-based triple therapy as first-line treatment of Helicobacter pylori infection: an in vitro and in vivo study. J Antimicrob Chemother 2019;74:1069-77. [PMID: 30668729 DOI: 10.1093/jac/dky510] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 19.0] [Reference Citation Analysis]
348 Pinheiro Silva L, Damacena de Angelis C, Bonamin F, Kushima H, José Mininel F, Campaner dos Santos L, Karina Delella F, Luis Felisbino S, Vilegas W, Regina Machado da Rocha L, Aparecido dos Santos Ramos M, Maria Bauab T, Toma W, Akiko Hiruma-lima C. Terminalia catappa L.: A medicinal plant from the Caribbean pharmacopeia with anti-Helicobacter pylori and antiulcer action in experimental rodent models. Journal of Ethnopharmacology 2015;159:285-95. [DOI: 10.1016/j.jep.2014.11.025] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 4.2] [Reference Citation Analysis]
349 Heo J, Jeon SW, Jung JT, Kwon JG, Lee DW, Kim HS, Yang CH, Park JB, Park KS, Cho KB. Concomitant and hybrid therapy for Helicobacter pylori infection: A randomized clinical trial. J Gastroenterol Hepatol. 2015;30:1361-1366. [PMID: 25867608 DOI: 10.1111/jgh.12983] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
350 Fagoonee S, Pellicano R. Helicobacter pylori: molecular basis for colonization and survival in gastric environment and resistance to antibiotics. A short review. Infect Dis (Lond) 2019;51:399-408. [PMID: 30907202 DOI: 10.1080/23744235.2019.1588472] [Cited by in Crossref: 37] [Cited by in F6Publishing: 20] [Article Influence: 18.5] [Reference Citation Analysis]
351 Gisbert JP, Barrio J, Modolell I, Molina-Infante J, Aisa AP, Castro-Fernández M, Rodrigo L, Cosme A, Gisbert JL, Fernández-Bermejo M, Marcos S, Marín AC, McNicholl AG. Helicobacter pylori first-line and rescue treatments in the presence of penicillin allergy. Dig Dis Sci 2015;60:458-64. [PMID: 25236423 DOI: 10.1007/s10620-014-3365-2] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 4.1] [Reference Citation Analysis]
352 Liou J, Chen C, Fang Y, Chen P, Chang C, Chou C, Chen M, Tseng C, Lee J, Yang T, Chiu M, Yu J, Kuo C, Luo J, Hsu W, Hu W, Tsai M, Lin J, Shun C, Twu G, Lee Y, Bair M, Wu M, Liou J, Lee Y, Lin J, Wu C, Wu J, Chen C, Lin C, Fang Y, Bair M, Luo J, Wu M, Cheng T, Tseng P, Chiu H, Chang C, Yu C, Chiu M, Chen Y, Hu W, Chou C, Tai C, Lee C, Wang W, Chang W; Members of the Taiwan Gastrointestinal Disease and Helicobacter Consortium. 14 day sequential therapy versus 10 day bismuth quadruple therapy containing high-dose esomeprazole in the first-line and second-line treatment of Helicobacter pylori: a multicentre, non-inferiority, randomized trial. Journal of Antimicrobial Chemotherapy 2018;73:2510-8. [DOI: 10.1093/jac/dky183] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
353 Boyanova L, Markovska R, Yordanov D, Gergova G, Mitov I. Clarithromycin Resistance Mutations in Helicobacter pylori in Association with Virulence Factors and Antibiotic Susceptibility of the Strains. Microb Drug Resist. 2016;22:227-232. [PMID: 26618567 DOI: 10.1089/mdr.2015.0199] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
354 Puah SM, Goh KL, Ng HK, Chua KH. Current status of Helicobacter pylori resistance to Clarithromycin and Levofloxacin in Malaysia-findings from a molecular based study. PeerJ 2021;9:e11518. [PMID: 34178444 DOI: 10.7717/peerj.11518] [Reference Citation Analysis]
355 Sanches BS, Martins GM, Lima K, Cota B, Moretzsohn LD, Ribeiro LT, Breyer HP, Maguilnik I, Maia AB, Rezende-Filho J. Detection of Helicobacter pylori resistance to clarithromycin and fluoroquinolones in Brazil: A national survey. World J Gastroenterol. 2016;22:7587-7594. [PMID: 27672279 DOI: 10.3748/wjg.v22.i33.7587] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
356 Chen PY, Wu MS, Chen CY, Bair MJ, Chou CK, Lin JT, Liou JM; Taiwan Gastrointestinal Disease and Helicobacter Consortium. Systematic review with meta-analysis: the efficacy of levofloxacin triple therapy as the first- or second-line treatments of Helicobacter pylori infection. Aliment Pharmacol Ther. 2016;44:427-437. [PMID: 27363687 DOI: 10.1111/apt.13712] [Cited by in Crossref: 36] [Cited by in F6Publishing: 22] [Article Influence: 7.2] [Reference Citation Analysis]
357 Skindersoe ME, Rasmussen L, Andersen LP, Krogfelt KA. A Novel Assay for Easy and Rapid Quantification of Helicobacter pylori Adhesion. Helicobacter 2015;20:199-205. [PMID: 25603836 DOI: 10.1111/hel.12191] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
358 Chiang TH, Chang WJ, Chen SL, Yen AM, Fann JC, Chiu SY, Chen YR, Chuang SL, Shieh CF, Liu CY, Chiu HM, Chiang H, Shun CT, Lin MW, Wu MS, Lin JT, Chan CC, Graham DY, Chen HH, Lee YC. Mass eradication of Helicobacter pylori to reduce gastric cancer incidence and mortality: a long-term cohort study on Matsu Islands. Gut. 2021;70:243-250. [PMID: 32792335 DOI: 10.1136/gutjnl-2020-322200] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
359 Lee JW, Kim N, Nam RH, Park JH, Choi YJ, Kim JM, Kim JS, Jung HC. GenoType HelicoDR test in the determination of antimicrobial resistance of Helicobacter pylori in Korea. Scand J Gastroenterol. 2014;49:1058-1067. [PMID: 24957849 DOI: 10.3109/00365521.2014.894117] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 3.7] [Reference Citation Analysis]
360 Bachir M, Allem R, Tifrit A, Medjekane M, Drici AE, Diaf M, Douidi KT. Primary antibiotic resistance and its relationship with cagA and vacA genes in Helicobacter pylori isolates from Algerian patients. Braz J Microbiol. 2018;49:544-551. [PMID: 29452847 DOI: 10.1016/j.bjm.2017.11.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
361 Liou JM, Chen CC, Chang CY, Chen MJ, Chen CC, Fang YJ, Lee JY, Yang TH, Luo JC, Wu JY, Liou TC, Chang WH, Hsu YC, Tseng CH, Chang CC, Bair MJ, Liu TY, Hsieh CF, Tsao FY, Shun CT, Lin JT, Lee YC, Wu MS; Taiwan Gastrointestinal Disease and Helicobacter Consortium. Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of Helicobacter pylori in the community and hospital populations: a randomised trial. Gut 2016;65:1784-92. [PMID: 26338825 DOI: 10.1136/gutjnl-2015-310142] [Cited by in Crossref: 46] [Cited by in F6Publishing: 37] [Article Influence: 7.7] [Reference Citation Analysis]
362 Djennane-Hadibi F, Bachtarzi M, Layaida K, Ali Arous N, Nakmouche M, Saadi B, Tazir M, Ramdani-Bouguessa N, Burucoa C. High-Level Primary Clarithromycin Resistance of Helicobacter pylori in Algiers, Algeria: A Prospective Multicenter Molecular Study. Microb Drug Resist. 2016;22:223-226. [PMID: 26554340 DOI: 10.1089/mdr.2015.0209] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
363 Di Lodovico S, Napoli E, Di Campli E, Di Fermo P, Gentile D, Ruberto G, Nostro A, Marini E, Cellini L, Di Giulio M. Pistacia vera L. oleoresin and levofloxacin is a synergistic combination against resistant Helicobacter pylori strains. Sci Rep 2019;9:4646. [PMID: 30874618 DOI: 10.1038/s41598-019-40991-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
364 Shao Y, Lu R, Yang Y, Xu Q, Wang B, Ye G. Antibiotic resistance of Helicobacter pylori to 16 antibiotics in clinical patients. J Clin Lab Anal. 2018;32:e22339. [PMID: 28984385 DOI: 10.1002/jcla.22339] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
365 Liu C, Wang Y, Shi J, Zhang C, Nie J, Li S, Zheng T. The status and progress of first-line treatment against Helicobacter pylori infection: a review. Therap Adv Gastroenterol 2021;14:1756284821989177. [PMID: 34262609 DOI: 10.1177/1756284821989177] [Reference Citation Analysis]
366 Shin K, Cho MJ, Oh JH, Lim CH. Second-Line Bismuth-Containing Quadruple Therapy for Helicobacterpylori Infection: A 12-Year Study of Annual Eradication Rates. J Clin Med 2021;10:3273. [PMID: 34362057 DOI: 10.3390/jcm10153273] [Reference Citation Analysis]
367 Graham DY, Laine L. The Toronto Helicobacter pylori Consensus in Context. Gastroenterology 2016;151:9-12. [PMID: 27215659 DOI: 10.1053/j.gastro.2016.05.009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
368 Bachir M, Allem R, Benejat L, Tifrit A, Medjekane M, Drici AE, Megraud F, Douidi KT. Molecular detection of mutations involved in Helicobacter pylori antibiotic resistance in Algeria. Journal of Antimicrobial Chemotherapy 2018;73:2034-8. [DOI: 10.1093/jac/dky167] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
369 Eto H, Suzuki S, Kusano C, Ikehara H, Ichijima R, Ito H, Kawabe K, Kawamura M, Yoda Y, Nakahara M, Gotoda T. Impact of body size on first-line Helicobacter pylori eradication success using vonoprazan and amoxicillin dual therapy. Helicobacter 2021;26:e12788. [PMID: 33580612 DOI: 10.1111/hel.12788] [Reference Citation Analysis]
370 Ducournau A, Bénéjat L, Sifré E, Bessède E, Lehours P, Mégraud F. Helicobacter pylori resistance to antibiotics in 2014 in France detected by phenotypic and genotypic methods. Clinical Microbiology and Infection 2016;22:715-8. [DOI: 10.1016/j.cmi.2016.06.003] [Cited by in Crossref: 46] [Cited by in F6Publishing: 35] [Article Influence: 9.2] [Reference Citation Analysis]
371 Chen Q, Long X, Ji Y, Liang X, Li D, Gao H, Xu B, Liu M, Chen Y, Sun Y, Zhao Y, Xu G, Song Y, Yu L, Zhang W, Liu W, Graham DY, Lu H. Randomised controlled trial: susceptibility-guided therapy versus empiric bismuth quadruple therapy for first-line Helicobacter pylori treatment. Aliment Pharmacol Ther. 2019;49:1385-1394. [PMID: 31020673 DOI: 10.1111/apt.15273] [Cited by in Crossref: 36] [Cited by in F6Publishing: 25] [Article Influence: 18.0] [Reference Citation Analysis]
372 Rispo A, Capone P, Castiglione F, Pasquale L, Rea M, Caporaso N. Fluoroquinolone-based protocols for eradication of Helicobacter pylori. World J Gastroenterol. 2014;20:8947-8956. [PMID: 25083067 DOI: 10.3748/wjg.v20.i27.8947] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
373 Bilgilier C, Simonitsch-Klupp I, Kiesewetter B, Raderer M, Dolak W, Makristathis A, Steininger C. Prevalence of clarithromycin-resistant Helicobacter pylori strains in gastric mucosa-associated lymphoid tissue lymphoma patients. Ann Hematol 2016;95:1115-20. [PMID: 27091350 DOI: 10.1007/s00277-016-2672-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
374 Zhi X, Liu Y, Lin L, Yang M, Zhang L, Zhang L, Liu Y, Alfranca G, Ma L, Zhang Q, Fu H, Conde J, Ding X, Chen D, Ni J, Song J, Cui D. Oral pH sensitive GNS@ab nanoprobes for targeted therapy of Helicobacter pylori without disturbance gut microbiome. Nanomedicine: Nanotechnology, Biology and Medicine 2019;20:102019. [DOI: 10.1016/j.nano.2019.102019] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
375 Cuadrado-Lavín A, Salcines-Caviedes JR, Diaz-Perez A, Carrascosa MF, Ochagavía M, Fernandez-Forcelledo JL, Cobo M, Fernández-Gil P, Ayestarán B, Sánchez B. First-line eradication rates comparing two shortened non-bismuth quadruple regimens against Helicobacter pylori: an open-label, randomized, multicentre clinical trial. J Antimicrob Chemother. 2015;70:2376-2381. [PMID: 25855760 DOI: 10.1093/jac/dkv089] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
376 Steiner TM, Lettl C, Schindele F, Goebel W, Haas R, Fischer W, Eisenreich W. Substrate usage determines carbon flux via the citrate cycle in Helicobacter pylori. Mol Microbiol 2021. [PMID: 34164854 DOI: 10.1111/mmi.14775] [Reference Citation Analysis]
377 O'Connor A, O'Morain CA, Ford AC. Population screening and treatment of Helicobacter pylori infection. Nat Rev Gastroenterol Hepatol. 2017;14:230-240. [PMID: 28053340 DOI: 10.1038/nrgastro.2016.195] [Cited by in Crossref: 77] [Cited by in F6Publishing: 61] [Article Influence: 19.3] [Reference Citation Analysis]
378 Ozturk O, Doganay L, Colak Y, Yilmaz Enc F, Ulasoglu C, Ozdil K, Tuncer I. Therapeutic success with bismuth-containing sequential and quadruple regimens in Helicobacter pylori eradication. Arab Journal of Gastroenterology 2017;18:62-7. [DOI: 10.1016/j.ajg.2017.05.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
379 Gudra D, Pupola D, Skenders G, Leja M, Radovica-Spalvina I, Gorskis H, Vangravs R, Fridmanis D. Lack of significant differences between gastrointestinal tract microbial population structure of Helicobacter pylori-infected subjects before and 2 years after a single eradication event. Helicobacter 2020;25:e12748. [PMID: 32776403 DOI: 10.1111/hel.12748] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
380 Mentis AA, Boziki M, Grigoriadis N, Papavassiliou AG. Helicobacter pylori infection and gastric cancer biology: tempering a double-edged sword. Cell Mol Life Sci 2019;76:2477-86. [DOI: 10.1007/s00018-019-03044-1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 10.5] [Reference Citation Analysis]
381 Katelaris PH, Katelaris AL. A prospective evaluation of levofloxacin-based triple therapy for refractory Helicobacter pylori infection in Australia: Levofloxacin triple therapy for refractory H. pylori. Intern Med J 2017;47:761-6. [DOI: 10.1111/imj.13432] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
382 Vale FF, Oleastro M. Overview of the phytomedicine approaches against Helicobacter pylori. World J Gastroenterol. 2014;20:5594-5609. [PMID: 24914319 DOI: 10.3748/wjg.v20.i19.5594] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
383 Molina-Infante J, Gisbert JP. Optimizing clarithromycin-containing therapy for Helicobacter pylori in the era of antibiotic resistance. World J Gastroenterol. 2014;20:10338-10347. [PMID: 25132750 DOI: 10.3748/wjg.v20.i30.10338] [Cited by in CrossRef: 48] [Cited by in F6Publishing: 36] [Article Influence: 8.0] [Reference Citation Analysis]
384 Gatta L, Scarpignato C, Fiorini G, Belsey J, Saracino IM, Ricci C, Vaira D. Impact of primary antibiotic resistance on the effectiveness of sequential therapy for Helicobacter pylori infection: lessons from a 5-year study on a large number of strains. Aliment Pharmacol Ther 2018;47:1261-9. [DOI: 10.1111/apt.14597] [Cited by in Crossref: 29] [Cited by in F6Publishing: 18] [Article Influence: 9.7] [Reference Citation Analysis]
385 Mégraud F. Time to change approaches to Helicobacter pylori management. Lancet Gastroenterol Hepatol 2017;2:692-3. [PMID: 28781120 DOI: 10.1016/S2468-1253(17)30245-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
386 Abadi ATB, Ierardi E. Vonoprazan and Helicobacter pylori Treatment: A Lesson From Japan or a Limited Geographic Phenomenon? Front Pharmacol. 2019;10:316. [PMID: 31024299 DOI: 10.3389/fphar.2019.00316] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
387 Gallardo Padilla M, León Falconi JL, Sánchez-Nebreda Arias R, Gómez Santos C, Muñoz Egea MDC, la Orden Izquierdo E. [Impact of the use of molecular techniques (PCR) on detection and eradication success against Helicobacter pylori]. An Pediatr (Engl Ed) 2021:S1695-4033(20)30502-6. [PMID: 33431330 DOI: 10.1016/j.anpedi.2020.11.016] [Reference Citation Analysis]
388 Saracino IM, Pavoni M, Zullo A, Fiorini G, Saccomanno L, Lazzarotto T, Antonelli G, Cavallo R, Borghi C, Vaira D. Rifabutin-Based Triple Therapy Or Bismuth-Based Quadruple Regimen As Rescue Therapies For Helicobacter pylori Infection. European Journal of Internal Medicine 2020;81:50-3. [DOI: 10.1016/j.ejim.2020.06.029] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 7.0] [Reference Citation Analysis]
389 Tanih NF, Ndip RN. Molecular Detection of Antibiotic Resistance in South African Isolates of Helicobacter pylori. Gastroenterol Res Pract. 2013;2013:259457. [PMID: 23710166 DOI: 10.1155/2013/259457] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
390 Adriaenssens N, Bruyndonckx R, Versporten A, Hens N, Monnet DL, Molenberghs G, Goossens H, Weist K, Coenen S; ESAC-Net study group. Consumption of macrolides, lincosamides and streptogramins in the community, European Union/European Economic Area, 1997-2017. J Antimicrob Chemother 2021;76:ii30-6. [PMID: 34312653 DOI: 10.1093/jac/dkab175] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
391 Park JY, Dunbar KB, Mitui M, Arnold CA, Lam-Himlin DM, Valasek MA, Thung I, Okwara C, Coss E, Cryer B, Doern CD. Helicobacter pylori Clarithromycin Resistance and Treatment Failure Are Common in the USA. Dig Dis Sci 2016;61:2373-80. [PMID: 26923948 DOI: 10.1007/s10620-016-4091-8] [Cited by in Crossref: 38] [Cited by in F6Publishing: 30] [Article Influence: 7.6] [Reference Citation Analysis]
392 Gisbert JP, Romano M, Gravina AG, Solís-muñoz P, Bermejo F, Molina-infante J, Castro-fernández M, Ortuño J, Lucendo AJ, Herranz M, Modolell I, del Castillo F, Gómez J, Barrio J, Velayos B, Gómez B, Domínguez JL, Miranda A, Martorano M, Algaba A, Pabón M, Angueira T, Fernández-salazar L, Federico A, Marín AC, Mcnicholl AG. Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments. Aliment Pharmacol Ther 2015;41:768-75. [DOI: 10.1111/apt.13128] [Cited by in Crossref: 65] [Cited by in F6Publishing: 43] [Article Influence: 10.8] [Reference Citation Analysis]
393 Galal AMF, Mohamed HS, Abdel-Aziz MM, Hanna AG. Development, synthesis, and biological evaluation of sulfonyl-α-l-amino acids as potential anti-Helicobacter pylori and IMPDH inhibitors. Arch Pharm (Weinheim) 2021;354:e2000385. [PMID: 33576040 DOI: 10.1002/ardp.202000385] [Reference Citation Analysis]
394 Marin AC, McNicholl AG, Gisbert JP. A review of rescue regimens after clarithromycin-containing triple therapy failure (for Helicobacter pylori eradication). Expert Opin Pharmacother. 2013;14:843-861. [PMID: 23537368 DOI: 10.1517/14656566.2013.782286] [Cited by in Crossref: 55] [Cited by in F6Publishing: 38] [Article Influence: 6.9] [Reference Citation Analysis]
395 . UEG Week 2020 Oral Presentations. United European Gastroenterol j 2020;8:8-142. [DOI: 10.1177/2050640620927344] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
396 Delchier JC, Bastuji-Garin S, Raymond J, Megraud F, Amiot A, Cambau E, Burucoa C;  HELICOSTIC Study Group. Efficacy of a tailored PCR-guided triple therapy in the treatment of Helicobacter pylori infection. Med Mal Infect. 2020;50:492-499. [PMID: 31257067 DOI: 10.1016/j.medmal.2019.06.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
397 Papastergiou V, Georgopoulos SD, Karatapanis S. Treatment of Helicobacter pylori infection: Past, present and future. World J Gastrointest Pathophysiol. 2014;5:392-399. [PMID: 25400982 DOI: 10.4291/wjgp.v5.i4.392] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 34] [Article Influence: 5.0] [Reference Citation Analysis]
398 O’Connor A, O’Moráin C. Helicobacter pylori infection in Europe: current perspectives. Expert Rev Gastroenterol Hepatol. 2013;7:541-548. [PMID: 23985003 DOI: 10.1586/17474124.2013.824707] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
399 Li XZ, Plésiat P, Nikaido H. The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria. Clin Microbiol Rev 2015;28:337-418. [PMID: 25788514 DOI: 10.1128/CMR.00117-14] [Cited by in Crossref: 658] [Cited by in F6Publishing: 295] [Article Influence: 109.7] [Reference Citation Analysis]
400 Trespalacios-Rangél AA, Otero W, Arévalo-Galvis A, Poutou-Piñales RA, Rimbara E, Graham DY. Surveillance of Levofloxacin Resistance in Helicobacter pylori Isolates in Bogotá-Colombia (2009-2014). PLoS One 2016;11:e0160007. [PMID: 27454429 DOI: 10.1371/journal.pone.0160007] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 4.2] [Reference Citation Analysis]
401 Campanale M, Nucera E, Ojetti V, Cesario V, Di Rienzo TA, D'Angelo G, Pecere S, Barbaro F, Gigante G, De Pasquale T, Rizzi A, Cammarota G, Schiavino D, Franceschi F, Gasbarrini A. Nickel free-diet enhances the Helicobacter pylori eradication rate: a pilot study. Dig Dis Sci 2014;59:1851-5. [PMID: 24595654 DOI: 10.1007/s10620-014-3060-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 2.9] [Reference Citation Analysis]
402 Zemali N, Guillemot G, Jaubert J, Picot S, Thomas E, Becquart J, Camuset G, Gérardin P, Michault A, Kwiatek S. Helicobacter pylori resistance to clarithromycin in Reunion Island. Médecine et Maladies Infectieuses 2016;46:385-9. [DOI: 10.1016/j.medmal.2016.06.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
403 Palmitessa V, Monno R, Panarese A, Cuppone R, Burattini O, Marangi S, Curlo M, Fumarola L, Petrosillo A, Parisi A, Capozzi L, Bianco A, Lippolis A. Evaluation of Antibiotic Resistance of Helicobacter pylori Strains Isolated in Bari, Southern Italy, in 2017-2018 by Phenotypic and Genotyping Methods. Microb Drug Resist 2020;26:909-17. [PMID: 32101078 DOI: 10.1089/mdr.2019.0262] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
404 Ji Z, Han F, Meng F, Tu M, Yang N, Zhang J. The Association of Age and Antibiotic Resistance of Helicobacter Pylori: A Study in Jiaxing City, Zhejiang Province, China. Medicine (Baltimore). 2016;95:e2831. [PMID: 26937912 DOI: 10.1097/md.0000000000002831] [Cited by in Crossref: 25] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
405 Bang CS, Lee JJ, Baik GH. The most influential articles in Helicobacter pylori research: A bibliometric analysis. Helicobacter 2019;24:e12589. [PMID: 31033071 DOI: 10.1111/hel.12589] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
406 Jung YS, Park CH, Park JH, Nam E, Lee HL. Efficacy of Helicobacter pylori eradication therapies in Korea: A systematic review and network meta-analysis. Helicobacter. 2017;22. [PMID: 28425141 DOI: 10.1111/hel.12389] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
407 Guevara B, Cogdill AG. Helicobacter pylori: A Review of Current Diagnostic and Management Strategies. Dig Dis Sci 2020;65:1917-31. [PMID: 32170476 DOI: 10.1007/s10620-020-06193-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 15.0] [Reference Citation Analysis]
408 O'Doherty KC, Virani A, Wilcox ES. The Human Microbiome and Public Health: Social and Ethical Considerations. Am J Public Health 2016;106:414-20. [PMID: 26794165 DOI: 10.2105/AJPH.2015.302989] [Cited by in Crossref: 22] [Cited by in F6Publishing: 9] [Article Influence: 4.4] [Reference Citation Analysis]
409 Hanafi A, Lee WC, Loke MF, Teh X, Shaari A, Dinarvand M, Lehours P, Mégraud F, Leow AH, Vadivelu J, Goh KL. Molecular and Proteomic Analysis of Levofloxacin and Metronidazole Resistant Helicobacter pylori. Front Microbiol 2016;7:2015. [PMID: 28018334 DOI: 10.3389/fmicb.2016.02015] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
410 Asaoka D, Nagahara A, Matsuhisa T, Takahashi S, Tokunaga K, Kawai T, Kawakami K, Suzuki H, Suzuki M, Nishizawa T. Trends of second-line eradication therapy for Helicobacter pylori in Japan: a multicenter study in the Tokyo metropolitan area. Helicobacter. 2013;18:468-472. [PMID: 23773231 DOI: 10.1111/hel.12063] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
411 Hu Y, Zhu Y, Lu NH. Primary Antibiotic Resistance of Helicobacter pylori in China. Dig Dis Sci. 2017;62:1146-1154. [PMID: 28315035 DOI: 10.1007/s10620-017-4536-8] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 9.8] [Reference Citation Analysis]
412 Zhang L, Lan Y, Wang Q, Zhang Y, Si X. Application of Minocycline-Containing Bismuth Quadruple Therapies as First-Line Regimens in the Treatment of Helicobacter pylori. Gastroenterol Res Pract 2019;2019:9251879. [PMID: 31933634 DOI: 10.1155/2019/9251879] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
413 Beer A, Hudler H, Hader M, Kundi M, Hudler S, Täuber V, Schachner H, Gruber S, Hirschl AM, Kain R, Makristathis A. Apparent intracellular Helicobacter pylori detected by immunohistochemistry - the missing link in eradication failure. Clin Infect Dis 2020:ciaa839. [PMID: 32569354 DOI: 10.1093/cid/ciaa839] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
414 Zou Y, Qian X, Liu X, Song Y, Song C, Wu S, An Y, Yuan R, Wang Y, Xie Y. The effect of antibiotic resistance on Helicobacter pylori eradication efficacy: A systematic review and meta-analysis. Helicobacter 2020;25:e12714. [PMID: 32533599 DOI: 10.1111/hel.12714] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 11.0] [Reference Citation Analysis]
415 Fiorini G, Vakil N, Zullo A, Saracino IM, Castelli V, Ricci C, Zaccaro C, Gatta L, Vaira D. Culture-based Selection Therapy for Patients Who Did Not Respond to Previous Treatment for Helicobacter pylori Infection. Clinical Gastroenterology and Hepatology 2013;11:507-10. [DOI: 10.1016/j.cgh.2012.12.007] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 3.9] [Reference Citation Analysis]
416 Boyanova L, Hadzhiyski P, Kandilarov N, Markovska R, Mitov I. Multidrug resistance in Helicobacter pylori: current state and future directions. Expert Rev Clin Pharmacol. 2019;12:909-915. [PMID: 31424296 DOI: 10.1080/17512433.2019.1654858] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 13.5] [Reference Citation Analysis]
417 Sena Teixeira Mendes L, D Attygalle A, C Wotherspoon A. Helicobacter pylori infection in gastric extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT) lymphoma: a re-evaluation. Gut 2014;63:1526-7. [PMID: 24951256 DOI: 10.1136/gutjnl-2014-307389] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
418 Sue S, Ogushi M, Arima I, Kuwashima H, Nakao S, Naito M, Komatsu K, Kaneko H, Tamura T, Sasaki T, Kondo M, Shibata W, Maeda S. Vonoprazan- vs proton-pump inhibitor-based first-line 7-day triple therapy for clarithromycin-susceptible Helicobacter pylori: A multicenter, prospective, randomized trial. Helicobacter. 2018;23:e12456. [PMID: 29271026 DOI: 10.1111/hel.12456] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
419 Moayedi S, Yadegar A, Balalaie S, Yarmohammadi M, Zali MR, Suzuki H, Fricker G, Haririan I. Sugar Codes Conjugated Alginate: An Innovative Platform to Make a Strategic Breakthrough in Simultaneous Prophylaxis of GERD and Helicobacter pylori Infection. Drug Des Devel Ther 2020;14:2405-12. [PMID: 32606607 DOI: 10.2147/DDDT.S255611] [Reference Citation Analysis]
420 Rokkas T, Gisbert JP, Malfertheiner P, Niv Y, Gasbarrini A, Leja M, Megraud F, O'Morain C, Graham DY. Comparative Effectiveness of Multiple Different First-Line Treatment Regimens for Helicobacter pylori Infection: A Network Meta-analysis. Gastroenterology 2021;161:495-507.e4. [PMID: 33839101 DOI: 10.1053/j.gastro.2021.04.012] [Reference Citation Analysis]
421 Jin H, Dai J, Meng L, Lu B. Curcuma wenyujin Y. H. Chen et C. Ling n-Butyl Alcohol Extract Inhibits AGS Cell Helicobacter pyloriCagA+VacA+ Promoted Invasiveness by Down-Regulating Caudal Type Homeobox Transcription Factor and Claudin-2 Expression. Chin J Integr Med 2020;26:122-9. [DOI: 10.1007/s11655-017-2958-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
422 Bordin DS, Embutnieks YV, Vologzhanina LG, Il'chishina TA, Voinovan IN, Sarsenbaeva AS, Alekseenko SA, Zaitsev OV, Abdulkhakov RA, Osipenko MF, Livzan MA, Tsukanov VV, Burkov SG, Bakulina NV, Dekhnich NN, Tarasova LV, Plotnikova EY, Maev IV, Kucheryavyi YA, Baryshnikova NV, Butov MA, Kolbasnikov SV, Pakhomova AL, Zhestkova TV, Baranovskii AY, Abdulkhakov SR, Ageeva EA, Lyalyukova EA, Vasyutin AV, Golubev NN, Savilova IV, Morkovkina LV, Kononova AG, Megraud F, O'Morain C, Ramas M, Nyssen OP, McNicholl AG, Gisbert JP. European Registry on the management of Helicobacter pylori infection (Hp-EuReg): analysis of 2360 patients receiving first-line therapy in Russia. Ter Arkh 2018;90:35-42. [PMID: 30701770 DOI: 10.26442/terarkh201890235-42] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
423 Hofreuter D, Behrendt J, Franz A, Meyer J, Jansen A, Bluemel B, Eisele B, Koken M, Glocker EO. Antimicrobial resistance of Helicobacter pylori in an eastern German region. Helicobacter 2021;26:e12765. [PMID: 33067911 DOI: 10.1111/hel.12765] [Reference Citation Analysis]
424 Tursi A, Franceschi M, Allegretta L, Savarino E, De bastiani R, Elisei W, Baldassarre G, Ferronato A, Scida S, Miraglia C, Penna A, Licci C, Rizzo G, Pranzo G, Cassieri C, Brandimarte G, Picchio M, Di mario F. Effectiveness and Safety of Pylera® in Patients Infected by Helicobacter Pylori: A Multicenter, Retrospective, Real Life Study. Dig Dis 2018;36:264-8. [DOI: 10.1159/000487391] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
425 Van Boeckel TP, Gandra S, Ashok A, Caudron Q, Grenfell BT, Levin SA, Laxminarayan R. Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data. Lancet Infect Dis. 2014;14:742-750. [PMID: 25022435 DOI: 10.1016/s1473-3099(14)70780-7] [Cited by in Crossref: 1093] [Cited by in F6Publishing: 372] [Article Influence: 156.1] [Reference Citation Analysis]
426 Georgopoulos SD, Xirouchakis E, Martinez-Gonzalez B, Sgouras DN, Spiliadi C, Mentis AF, Laoudi F. Clinical evaluation of a ten-day regimen with esomeprazole, metronidazole, amoxicillin, and clarithromycin for the eradication of Helicobacter pylori in a high clarithromycin resistance area. Helicobacter. 2013;18:459-467. [PMID: 23714140 DOI: 10.1111/hel.12062] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 5.3] [Reference Citation Analysis]
427 Coelho LGV, Marinho JR, Genta R, Ribeiro LT, Passos MDCF, Zaterka S, Assumpção PP, Barbosa AJA, Barbuti R, Braga LL, Breyer H, Carvalhaes A, Chinzon D, Cury M, Domingues G, Jorge JL, Maguilnik I, Marinho FP, Moraes-filho JPD, Parente JML, Paula-e-silva CMD, Pedrazzoli-júnior J, Ramos AFP, Seidler H, Spinelli JN, Zir JV. IVTH BRAZILIAN CONSENSUS CONFERENCE ON HELICOBACTER PYLORI INFECTION. Arq Gastroenterol 2018;55:97-121. [DOI: 10.1590/s0004-2803.201800000-20] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 5.7] [Reference Citation Analysis]
428 Emara MH, Mohamed SY, Abdel-Aziz HR. Lactobacillus reuteri in management of Helicobacter pylori infection in dyspeptic patients: a double-blind placebo-controlled randomized clinical trial. Therap Adv Gastroenterol. 2014;7:4-13. [PMID: 24381643 DOI: 10.1177/1756283x13503514] [Cited by in Crossref: 38] [Cited by in F6Publishing: 10] [Article Influence: 5.4] [Reference Citation Analysis]
429 Fitzgerald R, Smith SM. An Overview of Helicobacter pylori Infection. In: Smith SM, editor. Helicobacter Pylori. New York: Springer US; 2021. pp. 1-14. [DOI: 10.1007/978-1-0716-1302-3_1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
430 Delchier JC, Malfertheiner P, Thieroff-Ekerdt R. Use of a combination formulation of bismuth, metronidazole and tetracycline with omeprazole as a rescue therapy for eradication of Helicobacter pylori. Aliment Pharmacol Ther. 2014;40:171-177. [PMID: 24863854 DOI: 10.1111/apt.12808] [Cited by in Crossref: 59] [Cited by in F6Publishing: 46] [Article Influence: 8.4] [Reference Citation Analysis]
431 Kornoukhova LA, Emanuel VL, Denisov NL, Nikonov EL. Helicobacter pylori infection: place of serological and cultural diagnostics in clinical guidelines. Klin Lab Diagn 2021;66:496-501. [PMID: 34388321 DOI: 10.51620/0869-2084-2021-66-8-496-501] [Reference Citation Analysis]
432 Wang B, Wang YH, Lv ZF, Xiong HF, Wang H, Yang Y, Xie Y. Review: efficacy and safety of hybrid therapy for Helicobacter pylori infection: a systematic review and meta-analysis. Helicobacter. 2015;20:79-88. [PMID: 25381839 DOI: 10.1111/hel.12180] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
433 Egli K, Wagner K, Keller PM, Risch L, Risch M, Bodmer T. Comparison of the Diagnostic Performance of qPCR, Sanger Sequencing, and Whole-Genome Sequencing in Determining Clarithromycin and Levofloxacin Resistance in Helicobacter pylori. Front Cell Infect Microbiol 2020;10:596371. [PMID: 33392106 DOI: 10.3389/fcimb.2020.596371] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
434 Tay CY, Windsor HM, Thirriot F, Lu W, Conway C, Perkins TT, Marshall BJ. Helicobacter pylori eradication in Western Australia using novel quadruple therapy combinations. Aliment Pharmacol Ther. 2012;36:1076-1083. [PMID: 23072648 DOI: 10.1111/apt.12089] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 4.1] [Reference Citation Analysis]
435 Lee JY, Kim N. [Future trends of Helicobacter pylori eradication therapy in Korea]. Korean J Gastroenterol. 2014;63:158-170. [PMID: 24651589 DOI: 10.4166/kjg.2014.63.3.158] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 3.7] [Reference Citation Analysis]
436 Molina-Infante J, Romano M, Fernandez-Bermejo M, Federico A, Gravina AG, Pozzati L, Garcia-Abadia E, Vinagre-Rodriguez G, Martinez-Alcala C, Hernandez-Alonso M. Optimized nonbismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with high rates of antibiotic resistance. Gastroenterology. 2013;145:121-128.e1. [PMID: 23562754 DOI: 10.1053/j.gastro.2013.03.050] [Cited by in Crossref: 128] [Cited by in F6Publishing: 112] [Article Influence: 16.0] [Reference Citation Analysis]
437 Su P, Li Y, Li H, Zhang J, Lin L, Wang Q, Guo F, Ji Z, Mao J, Tang W, Shi Z, Shao W, Zhu X, Zhang X, Tong Y, Tu H, Jiang M, Wang Z, Jin F, Yang N. Antibiotic resistance of Helicobacter pylori isolated in the Southeast Coastal Region of China. Helicobacter. 2013;18:274-279. [PMID: 23418857 DOI: 10.1111/hel.12046] [Cited by in Crossref: 96] [Cited by in F6Publishing: 80] [Article Influence: 12.0] [Reference Citation Analysis]
438 Low M, Nitzan O, Bitterman H, Cohen C, Hammerman A, Lieberman N, Raz R, Balicer RD. Trends in outpatient antibiotic use in Israel during the years 2000-2010: setting targets for an intervention. Infection 2013;41:401-7. [PMID: 23001542 DOI: 10.1007/s15010-012-0332-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
439 Zhang M. High antibiotic resistance rate: A difficult issue for Helicobacter pylori eradication treatment. World J Gastroenterol. 2015;21:13432-13437. [PMID: 26730153 DOI: 10.3748/wjg.v21.i48.13432] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 21] [Article Influence: 6.4] [Reference Citation Analysis]
440 Wu MC, Wang YK, Liu CJ, Yu FJ, Kuo FC, Liu ML, Kuo CH, Wu DC, Huang YK, Wu IC. Adding Bismuth to Rabeprazole-Based First-Line Triple Therapy Does Not Improve the Eradication of Helicobacter pylori. Gastroenterol Res Pract 2017;2017:5320180. [PMID: 28791044 DOI: 10.1155/2017/5320180] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
441 Sugano K, Tack J, Kuipers EJ, Graham DY, El-Omar EM, Miura S, Haruma K, Asaka M, Uemura N, Malfertheiner P;  faculty members of Kyoto Global Consensus Conference. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64:1353-1367. [PMID: 26187502 DOI: 10.1136/gutjnl-2015-309252] [Cited by in Crossref: 609] [Cited by in F6Publishing: 433] [Article Influence: 101.5] [Reference Citation Analysis]
442 Morilla AM, Álvarez-Argüelles ME, Duque JM, Armesto E, Villar H, Melón S. Primary antimicrobial resistance rates and prevalence of Helicobacter pylori infection in the north of Spain. A 13-year retrospective study. Gastroenterol Hepatol 2019;42:476-85. [PMID: 31324461 DOI: 10.1016/j.gastrohep.2019.05.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
443 Boyanova L, Gergova G, Markovska R, Kandilarov N, Davidkov L, Spassova Z, Mitov I. Primary Helicobacter pylori resistance in elderly patients over 20 years: A Bulgarian study. Diagn Microbiol Infect Dis. 2017;88:264-267. [PMID: 28506722 DOI: 10.1016/j.diagmicrobio.2017.05.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
444 Megraud F, Bruyndonckx R, Coenen S, Wittkop L, Huang TD, Hoebeke M, Bénéjat L, Lehours P, Goossens H, Glupczynski Y; European Helicobacter pylori Antimicrobial Susceptibility Testing Working Group. Helicobacter pylori resistance to antibiotics in Europe in 2018 and its relationship to antibiotic consumption in the community. Gut 2021:gutjnl-2021-324032. [PMID: 33837118 DOI: 10.1136/gutjnl-2021-324032] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
445 Calcaterra SL, Drabkin AD, Doyle R, Leslie SE, Binswanger IA, Frank JW, Reich JA, Koester S. A Qualitative Study of Hospitalists' Perceptions of Patient Satisfaction Metrics on Pain Management. Hosp Top 2017;95:18-26. [PMID: 28362247 DOI: 10.1080/00185868.2017.1300479] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
446 Kim SY, Lee SW, Choe JW, Jung SW, Hyun JJ, Jung YK, Koo JS, Yim HJ. Helicobacter pylori eradication rates of concomitant and sequential therapies in Korea. Helicobacter 2017;22. [PMID: 28940815 DOI: 10.1111/hel.12441] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
447 Shah SC, Iyer PG, Moss SF. AGA Clinical Practice Update on the Management of Refractory Helicobacter pylori Infection: Expert Review. Gastroenterology 2021;160:1831-41. [PMID: 33524402 DOI: 10.1053/j.gastro.2020.11.059] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]